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Abstract 
 In the United States, cancer is the second leading cause of death following heart disease.  
Although, a variety of treatment regimens are available, cancer management is complicated 
by the complexity of the disease and the variability, between people, of disease progression 
and response to therapy. Therefore, advancements in the methods and technologies for 
cancer diagnosis, prognosis and therapeutic monitoring are critical to improving the 
treatment of cancer patients. 
 The development of improved imaging methods for early diagnosis of cancer and of 
near real-time monitoring of tumor response to therapy may improve outcomes as well as 
the quality of life of cancer patients. In the last decade, imaging methods including 
ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), single photon 
emission computed tomography (SPECT), and positron emission tomography (PET), have 
revolutionized oncology. More recently optical techniques, that have access to unique 
molecular reporting strategies and functional contrasts, show promise for oncologic imaging  
 This dissertation focuses on the development and optimization of a fiber-based, video-
rate fluorescence molecular tomography (FMT) instrument. Concurrent acquisition of 
fluorescence and reference signals allowed the efficient generation of ratio-metric data for 
3D image reconstruction. Accurate depth localization and high sensitivity to fluorescent 
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targets were established to depths of >10 mm. In vivo accumulation of indocyanine green 
dye was imaged in the region of the sentinel lymph node (SLN) following intradermal 
injection into the forepaw of rats. These results suggest that video-rate FMT has potential as 
a clinical tool for noninvasive mapping of SLN.  
 Spatial and temporal co-registration of nuclear and optical images can enable the fusion 
of the information from these complementary molecular imaging modalities. A critical 
challenge is in integrating the optical and nuclear imaging hardware. Flexible fiber-based 
FMT systems provide a viable solution. The various imaging bore sizes of small animal 
nuclear imaging systems can potentially accommodate the FMT fiber imaging arrays. In 
addition FMT imaging facilitates co-registering the nuclear and optical contrasts in time. In 
this dissertation, the feasibility of integrating the fiber-based, video-rate FMT system with a 
commercial preclinical NanoSPECT/CT platform was established. Feasibility of in vivo 
imaging is demonstrated by tracking a monomolecular multimodal-imaging agent (MOMIA) 
during transport from the forepaw to the axillary lymph nodes region of a rat. These co-
registered FMT/SPECT/CT imaging results with MOMIAs may facilitate the development 
of the next generation preclinical and clinical multimodal optical-nuclear platforms for a 
broad array of imaging applications, and help elucidate the underlying biological processes 
relevant to cancer diagnosis and therapy monitoring.  
 Finally, I demonstrated that video-rate FMT is sufficiently fast to enable imaging of 
cardiac, respiratory and pharmacokinetic induced dynamic fluorescent signals. From these 
measurements, the image-derived input function and the real-time uptake of injected agents 
can be deduced for pharmacokinetic analysis of fluorescing agents. In a study comparing 
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normal mice against mice liver disease, we developed anatomically guided dynamic FMT in 
conjunction with tracer kinetic modeling to quantify uptake rates of fluorescing agents. 
 This work establishes fiber-based, video-rate FMT system as a practical and powerful 
tool that is well suited to a broad array of potential imaging applications, ranging from early 
disease detection, quantifying physiology and monitoring progression of disease and 
therapies.  
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Preface 
 
Chapter 1: Accurate and rapid detection of diseases is of great importance for assessing the 
molecular basis of pathogenesis, preventing the onset of complications, and implementing a 
tailored therapeutic regimen. The ability of optical imaging to transcend wide spatial imaging 
scales ranging from cells to organ systems has rejuvenated interests in using this technology 
for medical imaging. Moreover, optical imaging has at its disposal diverse contrast 
mechanisms for distinguishing normal from pathologic processes and tissues. To 
accommodate these signaling strategies, an array of imaging techniques has been developed. 
Importantly, light absorption, and emission methods, as well as hybrid optical imaging 
approaches are amenable to both small animal and human studies. Typically, complex 
methods are needed to extract quantitative data from deep tissues. This chapter focuses on 
the development of optical imaging platforms, image processing techniques, and molecular 
probes, as well as their applications in cancer diagnosis, staging, and monitoring therapeutic 
response.  
 
Chapter 2: I have developed a fiber-based, video-rate fluorescence diffuse optical 
tomography (DOT) system for noninvasive in vivo sentinel lymph node (SLN) mapping. 
Concurrent acquisition of fluorescence and reference signals allowed the efficient generation 
of ratio-metric data for 3D image reconstruction. Accurate depth localization and high 
sensitivity to fluorescent targets were established in to depths of >10 mm. In vivo 
accumulation of indocyanine green (ICG) dye was imaged in the region of the SLN 
following intradermal injection into the forepaw of rats. These results suggest that video-rate 
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fluorescence DOT has significant potential as a clinical tool for noninvasive mapping of 
SLN. 
 
Chapter 3: Spatial and temporal co-registration of nuclear and optical images can enable the 
fusion of the information from these complementary molecular imaging modalities. A critical 
challenge is in integrating the optical and nuclear imaging hardware. Flexible fiber-based 
fluorescence mediated tomography (FMT) systems provide a viable solution. The various 
imaging bore sizes of small animal nuclear imaging systems can potentially accommodate the 
FMT fiber imaging arrays. In addition FMT imaging facilitates co-registering the nuclear and 
optical contrasts in time. In this chapter, I combine a fiber-based FMT system with a 
preclinical NanoSPECT/CT platform. Feasibility of in vivo imaging is demonstrated by 
tracking a monomolecular multimodal imaging agent (MOMIA) during transport from the 
forepaw to the axillary lymph nodes (ALNs) region of a rat. 
 The fiber-based, video-rate FMT imaging system is composed of 12 sources (785nm 
and 830nm LDs) and 13 detectors. To maintain high temporal sampling, the system 
simultaneously acquires ratio-metric data at each detector. A three-dimensional finite-
element model derived from CT projections provides anatomically based light propagation 
modeling. Injection of a MOMIA intradermally into the forepaw of rats provided spatially 
and temporally co-registered nuclear and optical contrasts. FMT data was acquired 
concurrently with SPECT and CT. Incorporation of SPECT as a prior in the FMT 
reconstruction integrated the optical and nuclear contrasts.  
 Accurate depth localization of phantoms with different thicknesses was accomplished 
with an average center-of-mass error of 4.1 +/- 2.1 mm between FMT and SPECT 
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measurements. During in vivo tests, Fluorescence and radioactivity from the MOMIA were 
co-localized in spatially coincident regions with an average center-of-mass error of 2.68 +/- 
1.0 mm between FMT and SPECT for ALNs localization. Intravital imaging with surgical 
exposure of the lymph node validated the localization of the optical contrast.  
 The feasibility of integrating a fiber-based, video-rate FMT system with a commercial 
preclinical NanoSPECT/CT platform was established. These co-registered 
FMT/SPECT/CT imaging results with MOMIAs may facilitate the development of the next 
generation preclinical and clinical multimodal optical-nuclear platforms for a broad array of 
imaging applications, and help elucidate the underlying biological processes relevant to 
cancer diagnosis and therapy monitoring.  
 
Chapter 4: Dynamic fluorescence imaging is an emerging technology that can provide 
enhanced non-invasive functional and molecular level detail. Optical tracer kinetic modeling 
combined with fluorescence dynamic tomography is a non-invasive quantification method 
that allows extraction of clinically or experimentally relevant parameters related to biological 
or molecular processes and monitoring their alterations due to pathology. Blood plasma 
concentration measurement of fluorescence over time is a key tool required for accurate 
optical tracer kinetic modeling to estimate the relevant and desired parameters. Anatomically 
guided dynamic fluorescence mediated tomography (DyFMT) provides a viable solution to 
obtain image derived input function. In this chapter, I demonstrate that video-rate FMT is 
fast enough to enable imaging of cardiac, respiratory and pharmacokinetic induced dynamic 
fluorescent signals.  From these measurements, the image-derived input function and the 
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real-time uptake of injected agents can be deduced in normal mice and in mice with 
experimentally induced liver disease.    
 
Chapter 5: Cancer-related enzyme activity can be detected noninvasively using activatable 
fluorescent molecular probes. In contrast to “always on” fluorescent molecular probes, 
activatable probes are relatively non-fluorescent at the time of administration due to 
intramolecular fluorescence resonance energy transfer (FRET). Enzyme mediated hydrolysis 
of peptide linkers results in reduced FRET and increased of fluorescence yield. Separation 
signal from active and inactive probe can be difficult with conventional intensity-based 
fluorescence imaging. Fluorescence lifetime (FLT) measurement is an alternative method to 
detect changes in FRET. Thus I investigated FLT imaging for in vivo detection of FRET-
based molecular probe activation in an orthotopic breast cancer model. Indeed, the 
measured FLT of the enzyme-activatable molecular probe increased from 0.62 ns just after 
injection to 0.78 ns in tumor tissue after 4 hours. A significant increase in FLT was not 
observed for an “always-on” targeted molecular probe with the same fluorescent reporter. 
These results show that FLT contrast is a powerful addition to preclinical imaging because it 
can report molecular activity in vivo due to changes in FRET. Fluorescence lifetime imaging 
exploits unique characteristics of fluorescent molecular probes that can be further translated 
into clinical applications including non-invasive detection of cancer-related enzyme activity. 
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Chapter 1 
 
General Introduction 
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1.1  Introduction 
 
 The application of optical imaging and spectroscopy in medicine and biomedical 
research has captivated the attention of many scientists, engineers, and clinicians because 
of the compactness, low cost, and ability of the technology to provide functional and 
molecular information (Hebden, Arridge and Delpy). In the process of optical imaging, 
light interaction with biological tissues leads to a number of photophysical events such as 
absorption, scattering, and emission of light. Each of these events can be utilized to 
obtain biochemical and morphological information about specific cell or tissue of 
interest. The diverse contrast mechanisms provided by optical methods constitute the 
basis of several optical imaging platforms that include spectroscopic, planar, diffuse, and 
hybrid biomedical optics methods (Tuchin; Vo-Dinh; Wang; Wax and Backman). In fact, 
the diversity of imaging and therapeutic platform available to researchers is a unique 
strength of optical technology.  
 Typically, optical imaging begins with the absorption of light by endogenous or 
exogenous chromophores to provide contrast between diseased and normal surrounding 
tissue. In absorption imaging, contrast is generated by the differential concentration of 
the chromophores in tissues (Niemz; Knappe, Frank and Rohde). The absorbed light 
can dissipate as heat to surrounding tissue, a phenomenon that is useful in photothermal 
therapy or photoacoustic imaging (Knappe, Frank and Rohde; Wang). A fraction of the 
absorbed light can be re-emitted at longer wavelengths than the incident. This emitted 
light is called autofluorescence if it originates from endogenous chromophores. 
Autofluorescence is widely used to characterize the metabolic status of tissue. An 
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important example is the classification of tissue as normal or benign and malignant 
tumors based on the optical properties of flavin adenine dinucleotide (FAD) and 
reduced nicotinamide adenine dinucleotide (NADH). Autofluorescence imaging and 
other endogenous fluorophores have easier path to human translation since the signaling 
biomolecules are naturally produced by the body. The term fluorescence is generally 
reserved for light emission generated by exogenous contrast agents. This class of optical 
imaging platform will be discussed in details in several sections below. In a variant of 
fluorescence imaging, spontaneous light emission can be induced by a biochemical 
reaction, such as the luciferase-catalyzed oxidation of luciferin (O'Neill et al.; Dothager 
et al.). This process is termed bioluminescence. Bioluminescence imaging is widely used 
to unravel the molecular basis of biochemical processes at the molecular levels in cells 
and small animals. The simplicity of the imaging method, high throughput capability, and 
the high detection sensitivity and specificity makes this approach attractive for drug 
development, monitoring treatment response, and molecular interactions in animal 
models of human diseases. Unfortunately, there is no clear path to human translation in 
the current state of the technology due to foreign genetic materials (O'Neill et al.; 
Dothager et al.). In addition to absorption and emission imaging, incident light is highly 
scattered in heterogeneous media such as tissues. Since light scattering pattern is 
dependent on tissue morphology, it is used to generate exquisite structural information 
of target tissues (Wax and Backman). For example, the up-regulation or down-regulation 
of structural proteins such as collagen can be used to report the invasiveness of tumors 
and the status of wound healing (Yeh et al.).  
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 Beyond cell and small animal studies, the next frontier is the translation of optical 
imaging and spectroscopy to humans. Major advances have been made in both 
instrumentation and tissue-targeted molecular probes that are suitable for human use. 
These advances promise to change the landscape of conventional diagnostic and 
treatment monitoring methods (Achilefu; Arridge; Arridge and Hebden; Celli et al.; 
Erickson and Godavarty; Gibson, Hebden and Arridge; Hebden, Arridge and Delpy; 
Vo-Dinh). Interestingly, optical imaging has come a long way from the early days of 
diaphanography, which used simple transillumination light scanning method (Monsees, 
Destouet and Totty), to modern day diffuse optical tomography and spectroscopy. 
Unlike diaphanography, which resulted in poor sensitivity in breast cancer detection 
(58%, based on histologic validation of biopsied samples)(Drexler, Davis and Schofield), 
new techniques have incorporated state-of-the-art imaging algorithms, highly sensitive 
detectors, and an array of light sources to delineate scattering from absorption 
parameters. This approach promises to improve both sensitivity and specificity of 
current imaging systems in clinics. Several optical imaging methods are already used in 
clinical practice. Notable among these is optical coherent tomography, which furnishes 
exceptionally high spatial resolution of tissue structure at microscopic level (Huang et al.; 
Boppart et al.). The method, which was first introduced for ophthalmologic applications 
(Swanson et al.), has been expanded to cardiac imaging (Bezerra et al.) and cancer 
diagnosis (Tearney et al.). Recent studies have also demonstrated the applicability of 
high-resolution optical fiber-based devices for in vivo characterization of tissues 
(Badizadegan et al.; Flusberg et al.; VoDinh et al.). Incorporation of this technique into 
endoscopes will expand their applications to virtually all current endoscopic procedures 
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and enhance the capabilities of intravital microscopy. Thus, in addition to aiding disease 
diagnosis, optical imaging is anticipated to be effective in monitoring treatment response 
in cancer patients (Choe, Corlu, et al.; Kukreti, Cerussi, Tanamai, et al.; Choe). 
 This chapter focuses on the development of optical imaging platforms, image 
processing techniques, and molecular probes, as well as their applications for cancer 
diagnosis, staging, and monitoring therapies. Emphasis is placed on emerging optical 
methods that are translatable to humans and specific to cancer. 
1.2 Optical Contrast Agents 
 Optical imaging techniques can measure both inherent tissue optical properties (e.g. 
scattering, absorption and autofluorescence) and those of exogenous molecular probes 
(e.g. fluorescence, photoacoustic) with high temporal resolution. The spectrally 
dependent light absorption and propagation properties in tissues (Figure 1.1) based on 
optical properties of specific molecules are used to produce imaging contrast in optical 
molecular imaging. A variety of optical contrast agent-mediated optical methods are 
widely used for preclinical imaging of cancer and monitoring of therapeutic responses. 
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Figure 1.1: Light propagation in turbid medium such as biological tissue. 
 
1.2.1 Endogenous Tissue Optical Contrast 
 Light interaction with biological tissues results in a number of photophysical events 
such as its absorption and scattering. Scattering is defined as the deviation of a photon 
path as it propagates through a heterogeneous medium such as a biological tissue. The 
most useful approximation describing light scattering in tissue is based on Mie’s theory 
(Tuchin; Wang and Wu; Richards-Kortum and Sevick-Muraca). Mie’s scattering relates 
to the scattering of light by particles of the same or larger size than the wavelength of the 
incident light. The intensity of Mie scattered radiation is weakly dependent on 
wavelength and tissue morphology (Tuchin; Wang and Wu).  Diffusely reflected and 
transmitted photons provide diagnostic information about the tissue. For instance, the 
change in size and number of the major light scatterers in tissue, such as mitochondria 
and cell nuclei, can be used to differentiate neoplastic from healthy tissues based on the 
    
 
7 
spectral variation of the scattered light. To illustrate this point, the diameter of cell nuclei 
in normal epithelial tissues has been found to be approximately 4-7 µm compared to 20 
µm in cancerous tissues, which also contain multiple nuclei (Tuchin; Wang and Wu). 
Hence, scattering properties of tissues provide insight into morphological and structural 
changes that can be used to identify abnormal variations of the tissue’s spatial 
characteristics. Detailed theoretical basis and practical applications of light scattering in 
tissues for biomedical imaging has recently been reported (Wax and Backman). 
 Absorption is a phenomenon that results in the capturing of light energy by 
chromophores, exciting their electrons from the ground to higher energy levels (Vo-
Dinh; Niemz; Tuchin; Wang and Wu). The chromophores dissipate their energy in the 
form of heat or by a radiative decay when their excited electrons return to the ground 
state (Wang and Wu; Niemz; Tuchin). Oxy-hemoglobin (HbO2) and deoxyhemoglobin 
(HbR), melanin, myoglobin, and water are the predominant endogenous absorbers in the 
600-1000nm. Interestingly, the absorption coefficient of these chromophores are low 
between 700 and 900 nm relative to the visible wavelengths, creating an optimal spectral 
window that allows light to travel in deep tissue and the photons to undergo multiple 
scattering events before attenuation (Richards-Kortum and Sevick-Muraca; Tuchin; 
Wang and Wu). For these reasons, most optical methods for deep tissue imaging and 
diffuse optical tomography in particular, operate in this “transparent optical window”. 
 As mentioned above, variations in total hemoglobin and oxygen saturation can be 
inferred from tissue absorption based on the differences in oxy-hemoglobin and deoxy-
hemoglobin optical spectra. For tumor imaging, high level of HbO2 may suggest an 
increase in arterial blood supply, creation of new blood supply pathway to tumors, or 
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high metabolic oxygen demand reminiscent of highly proliferating tumors. In contrast, 
an increase in HbR concentration implies a decrease in oxygen saturation associated with 
the presence of hypoxic tumor or high oxygen extraction. Both HbO2 and HbR serve as 
important biomarkers for tumor diagnosis and monitoring the outcome of a therapeutic 
intervention. To illustrate this approach, Choe et al. (Choe, Corlu, et al.) demonstrated 
the feasibility of localizing invasive carcinoma of breast tumor with diffuse optical 
tomography by quantifying the total hemoglobin and oxy-hemoglobin concentrations. 
The authors observed that the tumor volume and total hemoglobin concentration 
decreased from 21.4±1.4 µM to 9.1±0.5 µM over the course of the chemotherapy. A 
variety of similar studies have been reported and a recent paper by Leff et al. (Leff et al.) 
summarized the findings of optical-based breast imaging studies from different research 
groups. 
 Tissue autofluorescence occurs when excited electrons of endogenous fluorophores 
emit light of different wavelength after photon absorption (Wang and Wu; Tuchin; 
Berezin and Achilefu). The importance of autofluorescence for studying cells and tissues 
lies mostly in their potential for diagnostic applications. It is also used as a research tool 
to understand the underlying mechanisms of molecular interactions and signaling 
processes under their native conditions (Berezin and Achilefu; Monici; Richards-Kortum 
and Sevick-Muraca). The most important fluorophores for autofluorescence in cells and 
tissues are amino acids (phenylalanine, tyrosine and tryptophan), which are the essential 
building blocks of proteins and enzymes; nicotinamide and flavins, which regulate cell 
metabolism; porphyrins, which are responsible for the transport of respiratory gases; 
structural proteins (collagen and elastin), which are responsible for rigidity and flexibility 
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of tissues and organs; and fluorescent pigments (melanin, lipofuscin), which are markers 
of many age-related pathologies (Berezin and Achilefu; Monici). For instance, 
endogenous fluorophores such as flavin adenine dinucleotide (FAD) and reduced 
nicotinamide adenine dinucleotide (NADH) are used to monitor changes in the 
metabolic level of tissues by taking the ratio of their fluorescence intensity obtained from 
one- and two-photon confocal microscopy (Richards-Kortum and Sevick-Muraca) as 
well as with diffuse spectroscopy (C. Zhu et al.). The fluorescence intensity of NADH is 
found to be higher than its oxidized form (NAD+), and vice versa for the FAD. 
However, a number of challenges associated with the complex nature of 
autofluorescence, such as weak fluorescence signals, the use of damaging UV light or 
high power two-photon visible excitation, and difficulties in interpretation of images, 
limits its broad applications in molecular imaging and disease diagnosis. Thus, the use of 
autofluorescence depends on the intended application or tissue type. For example, skin 
diseases and a variety of endoscope-based applications that do not require deep tissue 
analysis have benefited from autofluorescence imaging. Exciting studies using 
endoscopes for examining gastrointestinal neoplasia in clinical settings have been 
reported (Imaeda et al.; Falk). Note that fluorophores from diet also contribute 
significantly to autofluorescence. This type of autofluorescence could increase 
background signal during tissue imaging with exogenous imaging agents. However, 
several methods are available to minimize this side effect, including fasting the animal, 
the use of special diet with low autofluorescence, and techniques to spectrally suppress 
autofluorescence (Bhaumik, Depuy and Klimash; Bouchard et al.) 
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1.2.2 Exogenous Tissue Contrast Agents 
 Exogenous contrast agents are playing a crucial role in advancing optical molecular 
imaging for wide array of applications, ranging from studying cell regulation mechanisms 
to cancer diagnosis. The advantage of exogenous optical contrast agents lies in the ability 
to optimize their structure for a wide variety of disease-specific studies. This is generally 
accomplished by tuning their spectral properties. Optical probes that absorb and emit in 
the visible spectral range are mainly used for superficial tissue imaging (for example skin 
cancer detection) and studies of cell mechanisms. However, the signal obtained from 
optical probes in the visible range is biased by background tissue autofluorescence signal, 
which is negligible in the NIR spectral range. Therefore, molecular probes in the NIR 
region are primarily used for deep tissue in vivo imaging and to minimize 
autofluorescence. Optical contrast agents are classified into different groups based on 
their fluorophore structure, spectral range, and specific activity. Examples of common 
optical probes are cyanine dyes, boron-dipyrromethene (BODIPY) based molecules, and 
quantum dots (Akers and Achilefu; Berezin and Achilefu). The sources of contrast could 
be due to change in intensity, fluorescence lifetime or polarization associated with 
biological processes. Preferably, optical molecular probes should have high molar 
absorptivity, high fluorescence quantum yield (for fluorescence imaging), and good 
photo-stability. For activatable probes, they should preferably be enzymatically stable to 
non-target enzymes and biochemical reactions. In addition, chemical stability is 
important for a new generation of molecular probes carrying targeting groups for 
selective delivery to tumors. Such targeted conjugates further enhance the sensitivity and 
specificity of optical contrast agents for early detection of cancer. 
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1.2.2.1 Non-Targeted Optical Contrast Agents 
 Non-targeted optical contrast agents typically accumulate in tumors because of 
increased tumor vascularization and/or leaky blood vessels (Achilefu; S. I. Achilefu et al.; 
Licha, Hessenius, et al.; Licha, Riefke, et al.). The approved use of the NIR fluorescent 
dye, indocyanine green (ICG), by the US Food and Drug Administration for non-
imaging indications has allowed adoption as non-specific and biocompatible optical 
imaging agent in humans. Thus, ICG is widely used to test the performance and 
specifications of optical imaging devices in clinical and preclinical studies. It is also used 
as a generic imaging agent for cancer imaging. For example, Intes et al. (Intes, Ripoll, et 
al.) localized suspicious mass in breast cancer patients after bolus administration of ICG. 
Additionally, Alacam et al. introduced a computational model to analyze ICG 
pharmacokinetics in cancerous tumors vs. normal tissues using NIR diffuse optical 
tomography (Alacam, Yazici, Intes, et al.; Alacam, Yazici, Intes, Nioka, et al.). In these 
studies, the authors provided temporal images of the distribution of ICG from breast 
cancer patients. Using a computational model, they reported significant difference in the 
pharmacokinetic rates as well as ICG concentration in the tumor compared to the 
surrounding normal tissue region. Recently, Sevick-Muraca et al. (Sevick-Muraca et al.) 
demonstrated the feasibility of employing NIR fluorescence imaging for dynamic lymph 
trafficking and lymph node mapping in humans non-invasively after bolus injection of 
ICG in the arms and legs of patients. The impressive dynamic images demonstrated the 
potential of using optical molecular imaging for sentinel lymph node mapping in cancer 
staging. However, since non-targeted optical probes suffer from low selectivity for 
tumors, the use of molecular probes that selectively target cancer tissue, could further 
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improve the information content obtained, particularly in the identification of positive 
nodes for biopsy. 
1.2.2.2 Cancer Biomarkers and Targeted Probes 
 Many of the current efforts in tumor imaging have focused on the design of cancer-
targeting molecular probes. One approach is to identify cancer biomarkers, such as over-
expressed proteins or diagnostic enzymes in the tumor and the appropriate molecule 
(ligand) that binds to a target biomarker with high affinity. Once the biomarkers and the 
ligands are established, the targeted molecular probe can be prepared by conjugating the 
targeting moiety to the dye. Cancer biomarker identification is essential for early 
diagnosis, prognosis and staging of cancers as well as monitoring and optimizing 
therapies. In general, cancer biomarkers for targeted optical imaging are biomolecules 
such as cell surface protein receptors or enzymes, which are over-expressed in the active 
form in neoplasms compared to normal tissues. Many of these biomarkers are 
commonly shared by a number of malignant tumors (Ludwig and Weinstein; Sidransky). 
Below I will review two classes of the molecular targeted probes: non activatable and 
activatable.  
 Receptor Targeted optical molecular probes. Optical imaging with receptor-targeted 
molecular probes relies on the increased concentration of the probe on the target tissue 
to generate increased optical (fluorescence or photoacoustic) signal. Historically, this was 
the first type of tumor-targeted molecular probes (S. Achilefu, R. B. Dorshow, et al.). 
Today, a majority of the tumor targeting molecular probes belongs to this class and a 
large number of the constructs are now commercially available. 
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 Initial studies relied on the labeling of large biomolecules such as antibodies for 
optical imaging (Ballou et al.; Clauss and Jain).  These pioneering studies gave rise to the 
highly promising advances in the molecular imaging of tumors. For example, the 
transmembrane tyrosine kinase receptor proteins in which a member of the epidermal 
growth factor receptor family (EGFR), the human epidermal growth factor receptor 2 
(HER-2/neu), is commonly over-expressed has become a favorite target for optical 
imaging of tumors. The key function of EGFR is intracellular signal transduction to 
control cell proliferation, migration and cell survival (Ross and Fletcher; Ross, Fletcher, 
Bloom, Linette, Stec, Symmans, et al.; Nicholson et al.). Up-regulation of HER-2/neu 
has been associated with tumor growth and metastasis (Ross and Fletcher; Cobleigh et 
al.). Trastuzumab (also known as Herceptin) is a humanized monoclonal antibody that 
has high affinity for HER-2 receptors (Ross, Fletcher, Bloom, Linette, Stec, Clark, et al.; 
Vogel et al.). Therefore, a number of efforts in optical imaging of cancer involved 
conjugating fluorescent dyes with Trastuzumab to image HER2 positive tumors 
(Koyama et al.; Sampath et al.).  
 Although large proteins and antibodies hold great promise for the development of 
tumor targeting agents with high binding affinity to the target receptor, interest in the 
use of small peptide-based molecular probes have continued to gain grounds in receptor-
targeting imaging platforms. A prominent example is the targeting of somatostatin 
receptors with fluorescent dye labeled somatostatin peptide analogues such as octreotate 
(S. Achilefu, H. N. Jimenez, et al.; Licha, Hessenius, et al.). The somatostatin receptor 
served as a target in whole-body animal imaging study with receptor-targeted NIR 
fluorescent probe. In this example, a NIR fluorescent dye analogue to ICG but with 
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conjugatable functionalities, cypate, was covalently linked to octreotate. Using a planar 
fluorescence reflectance imaging system, the in vivo distribution of the molecular probe 
in rodents bearing pancreatic acinar carcinomas was obtained (S. Achilefu, R. B. 
Dorshow, et al.). This study demonstrates the high uptake of the optical molecular probe 
in the tumor. Since this pioneering study, numerous studies have validated the use of 
NIR dye-labeled peptides to image tumors in living systems as described below. 
 Another example of a cancer biomarker that is over-expressed in a wide range of 
tumors are the αvβ3 integrins, which are heterodimeric cell surface proteins composed of 
one one α and one β transmembrane glycoprotein subunits (Giancotti "Complexity and 
Specificity of Integrin Signalling"). The key function of integrins is to regulate multiple 
intracellular signal transduction pathways leading to cell proliferation, differentiation, 
migration and survival (Giancotti "Integrin Signaling: Specificity and Control of Cell 
Survival and Cell Cycle Progression"; Giancotti "Complexity and Specificity of Integrin 
Signalling"; Giancotti and Ruoslahti). The αvβ3 integrin is of special interest because it is 
upregulated in various tumors as well as angiogenic blood vessels (Giancotti "Integrin 
Signaling: Specificity and Control of Cell Survival and Cell Cycle Progression"; Guo and 
Giancotti). The αvβ3 integrin has high affinity for the naturally occurring 
proteins/polypeptides possessing Arg-Gly-Asp (RGD) peptide sequence [68]. The utility 
of a NIR fluorescent probe decorated with RGD peptides in tumor imaging has been 
reported by many investigators (Achilefu; Haubner et al.; S. Achilefu, S. Bloch, et al.; Ye 
et al.). Achilefu et al. [70] also discovered that a variant of RGD peptides possessing the 
GRD peptide sequence labeled with cypate selectively accumulates in αvβ3 integrin 
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positive tumor (A549) in nude mice. The study was conducted with a simple planar 
fluorescence reflectance imaging system. Further microscopic analysis showed that 
retention of this molecular probe in the tumor correlated with regions of high expression 
of metabolic indicators such as NADH. Thus, this molecular probe appears to selectively 
target highly proliferating tumors. 
 Following by the success of preclinical studies, efforts to move the receptor-targeted 
optical imaging to humans have increased recently. The highly compartmentalized nature 
of the gastrointestinal system and the ease of accessing this organ with endoscopes have 
attracted the first human study of molecular optical imaging of gastrointestinal tumors 
with a peptide-based exogenous imaging agent (Hsiung et al.). The fluorescein-
conjugated peptide construct was developed to bind more strongly to dysplastic 
colonocytes than to adjacent normal cells and demonstrated 81% sensitivity and 82% 
specificity. Applications of this approach for image guided intraoperative procedures are 
also in progress. 
 Targeted activatable optical contrast agents are mostly designed to interrogate biological 
processes associated with abnormal protease activities and tissue metabolism. Activatable 
probes are generally composed of a covalently linked fluorophore pair with different or 
similar optical properties in close proximity to each other. For Förster or fluorescence 
resonance energy transfer (FRET) mechanism, the emission spectrum of the donor must 
overlap with the absorption spectrum of the acceptor (Berezin and Achilefu). In this 
configuration, the transmission of the excitation energy from the donor to the acceptor 
dye quenches the fluorescence of the donor (Berezin and Achilefu) decreasing the 
donor’s fluorescence intensity and lifetime (M. Solomon, K. Guo, et al.). Upon 
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enzymatic cleavage, the two fluorophores separates from each other, resulting in increase 
of donor’s fluorescence intensity and lifetime (M. Solomon, K. Guo, et al.). The amount 
of energy transfer measured from the fluorescence intensity and fluorescence lifetime of 
the activatable optical probes can be used to investigate changes in biological processes 
(Berezin, Lee, Akers, Guo, et al.). Figure 1.2 illustrates the process of FRET probes 
activation and application in tumor imaging. A number of FRET probes including those 
optically active in NIR were designed to recover fluorescence after releasing the 
quencher moiety, which occurs when the probe binds to the active site of diagnostic 
enzymes (Choe, Konecky, et al.; McIntyre and Matrisian "Molecular Imaging of 
Proteolytic Activity in Cancer"; McIntyre and Matrisian "Optical Proteolytic Beacons for 
in Vivo Detection of Matrix Metalloproteinase Activity"; McIntyre, Scherer and 
Matrisian; Z. Zhang et al.; Paulick and Bogyo). 
 Abnormally high proteolytic activities of extracellular and intracellular proteases 
such as matrix metalloprotease (MMP), cathespin and caspase families are found to 
mediate tumor growth, invasion, and metastasis (Himelstein et al.; McIntyre and 
Matrisian "Molecular Imaging of Proteolytic Activity in Cancer"; McIntyre and Matrisian 
"Optical Proteolytic Beacons for in Vivo Detection of Matrix Metalloproteinase 
Activity"; Fingleton). Particularly, MMPs and cathespin families are involved in basement 
membrane degradation, leading to local cell invasion and metastasis (Bremer, Tung and 
Weissleder). The utility of the protease activatable probes for in vivo tumor imaging was 
first demonstrated by Weissleder et al. (Weissleder et al.). They developed activatable 
NIR fluorescent molecular probe to localize lung tumor and image the expression and 
activity of lysosomal proteases. Bremer et al. used this strategy to image the expression 
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and activity of MMP-2 enzymes in vivo (Bremer, Tung and Weissleder). The study 
showed recovery of fluorescence after injection of the probe in mice bearing MMP-2 
positive human fibrosarcomas. Fluorescence signal from the non-specific control 
molecular probe was minimal. These and other activatable molecular probes have 
improved the detection sensitivity of tumors in animal models.  
 In addition to MMPs, other biomarkers have also been targeted as tumor reporters 
and for monitoring treatment responses. For example, Blum et al. developed molecular 
probes that could monitor cathepsin B activity (Blum et al.), which mediates tumor 
invasion and Gocheva et al. utilized fluorogenic peptides for neo-angiogenesis detection 
(Gocheva et al.). These studies were conducted with in vivo mouse models of human 
epithelial adenocarcinoma and pancreatic islet cell carcinogenesis respectively. 
 Another area of intense research is to monitor treatment response through cell 
death using activatable probes. Programmed cell death, known as apoptosis, is partly 
controlled by intracellular caspases. These enzymes are up regulated in cells undergoing 
apoptosis and studies have shown that disruption of apoptosis results in abnormal cell 
proliferation and tumor growth. The activities of these proteolytic enzymes have been 
recognized as important markers for developing imaging and therapeutic agents to non-
invasively monitor tumor progress and therapy response (Odonkor and Achilefu 
"Differential Activity of Caspase-3 Regulates Susceptibility of Lung and Breast Tumor 
Cell Lines to Paclitaxel"; Odonkor and Achilefu "Modulation of Effector Caspase 
Cleavage Determines Response of Breast and Lung Tumor Cell Lines to 
Chemotherapy"; Z. Zhang et al.). For instance, Bullok et al. developed FRET based 
caspase activatable molecular probe, TcapQ647, composed of fluorescent moiety in 
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close proximity to NIR fluorescent quencher linked with caspase cleavable peptide 
sequence (Bullok and Piwnica-Worms; Bullok et al.). The study demonstrated the utility 
of TcapQ647 for imaging amoeba induced cell death in mice with colon xenografts. 
They observed a greater increase in parasite-infected xenografts vs. the control after 
TcapQ647 injection, thus, demonstrating the potential of the compound for monitoring 
treatment response. An example of caspase-3 activatable probes that are based on FRET 
between two NIR cyanine dyes connected with caspase-3 cleavable peptide substrate, 
Asp-Glu-Val-Asp (DEVD), was designed by Zhang et al. (Z. Zhang et al.). Upon contact 
with caspase-3whose over-expression was induced by the administration of the 
chemotherapeutic drug (paclitaxel) to A549 tumor bearing mice, cleavage of the DEVD 
peptide sequence in the fluorescence-quenched probe resulted in the fluorescence 
restoration. 
 Although activatable molecular probes have improved the detection sensitivity of 
tumors in vivo by lowering background fluorescence, they suffer from nonspecific 
activation in the blood and healthy tissues. Therefore, the development of highly 
sensitive and specific activatable molecular probes for tumor imaging is an active area of 
current research endeavors. Efforts to translate some of the probes to humans have 
been initiated by different research groups. 
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 Figure 1.2: Schematic design of targeting non-activatable optical probe (top) and the 
process of utilizing targeted activatable FRET probe (bottom). Step 1: Internalization of 
protease activatable molecular probe via a membrane receptor. Step 2: Transmission of 
the excitation energy from the donor to the acceptor dye quenches the fluorescence of 
the donor. Step 3 and 4: Recovering of fluorescence after releasing the quencher moiety 
when the probe binds to the active site of diagnostic enzymes. 
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1.3 Hardware and Image Reconstruction 
 Based on the light illumination schemes, optical imaging systems are classified as 
continuous wave (CW), frequency domain (FD), and time domain (TD) imaging 
methods with planar, reflectance, or cylindrical modes of measurements (Gibson, 
Hebden and Arridge; Wang and Wu; Erickson and Godavarty; Vo-Dinh; Xu and 
Povoski; Tuchin; Hebden, Arridge and Delpy). CW optical imaging platform illuminates 
tissues with light of constant amplitude or low frequency modulation and detect the light 
attenuation caused by differential changes associated with the tissue absorption 
properties. FD imaging platform modulates the light sources at frequencies of tens to 
hundreds of megahertz and measures the amplitude decay and phase shift of the output 
light to quantify tissue absorption and scattering properties. TD optical platform detects 
the temporal distribution of diffuse light (photons) after illuminating the tissue with 
short light pulses for depth-resolved quantification of the tissue’s absorption and 
scattering properties (Chance et al.; Grosenick et al.; S. Patwardhan et al.). Hybrid 
imaging methods that utilize light as part of imaging signal generation also use 
tomographic approaches. For example, in photoacoustic methods, pulsed light is used to 
generate ultrasound waves from local tissue's thermal expansion following light 
absorption (Xu and Wang). Each of these techniques will be described in more details 
below. Representative advantages and limitations of the above techniques are 
summarized in Table 1.1. 
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Continous Wave Time Domain Frequency Domain 
Faster than TD and FD Quantitative Quantitative 
Accurate for differential 
measurement of optical 
properties 
High spatial and depth 
resolution 
High spatial and depth 
resolution 
Relatively compact 
Recovery of absorption, 
fluorescence, and scattering 
properties from temporal 
impulse response 
Faster than TD but less 
accurate 
Less expensive than TD 
and FD 
Accurate than FD but 
slower 
Recovery of absorption, 
fluorescence, and scattering 
properties from diffusive 
wave phase and amplitude 
Table 1.1:  Comparison of imaging systems techniques. 
 
 Reconstruction of optical images requires an understanding of the propagation of 
light in tissue and is largely based on the knowledge of tissue properties that affect 
photons and the mathematical algorithms to analyze and classify spectral data. These 
algorithms help to overcome the tissue’s high spatial heterogeneity and identify small 
differences between normal and cancerous tissues. Reconstruction procedure starts from 
multiple measurements, where an array of light sources and detectors for a defined 
geometry are used to generate and detect light. Acquisition of experimental data is 
followed by the application of a light transport model. This model is based on the 
propagation of photons in the region of interest. It describes the relationship between 
tissue optical properties (usually absorption and scattering coefficients) associated with 
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the relevant pixels and the resulting source-detector measurements (Arridge and 
Schotland; Arridge; Arridge and Hebden; Arridge and Schweiger; Dehghani et al.). Light 
transport in biological tissue is typically modeled stochastically by deriving probability 
functions for photon transitions (Monte Carlo, random walk theory) (Wang, Jacques and 
Zheng) or deterministically by deriving the diffusion equation from radiative transfer 
equation (RTE) (Patterson, Chance and Wilson; Arridge and Hebden; Dehghani et al.; 
Gibson and Dehghani; Wang and Wu). The first method produces more accurate results 
but it is computationally demanding. Data analysis can range from several hours to 
several days of computing. The method based on diffusion equation is faster. Therefore 
it is used more frequently in clinical setting (Schweiger et al.). In both methods, light 
transport model yields a set of dynamic equations describing the transport of photons as 
a function of optical properties of the tissue and instrument setting.  
 After establishing the light transport model, the second step in image reconstruction 
involves finding a solution to a forward problem (Arridge and Hebden; Gibson, Hebden 
and Arridge; Dehghani et al.; Arridge and Schweiger; Arridge and Schotland). The 
forward problem calculates the optical properties of the tissue (absorbance, scattering, or 
changes in absorption or light attenuation, e.t.c.) as a result of the applied light transport 
model from step one. Numerical models are commonly used to solve the forward 
problem and to predict the relationship between the optical parameters for all pixels as a 
function of the source-detector arrangement. Linear approximations to numerical 
methods are frequently used to simplify the estimation process (Schweiger et al.; Arridge; 
Gaudette et al.).  The output of the forward problem is typically presented as a sensitivity 
matrix, where the values obtained from the forward problem are stored. 
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 In the last step, the image is reconstructed by inverting the sensitivity matrix and 
solving the inverse problem to recover the optical properties of the tissue (Dehghani et 
al.; Arridge and Schotland; Gibson and Dehghani; Schweiger, Gibson and Arridge). To 
accomplish this goal, the optimization equation is solved to recover the optical 
properties of the tissue. The procedure is usually based on a least-squares equation 
(linear or non-linear) expressing the difference between the measured data and the 
expected measurements obtained from forward problem solution (Yalavarthy, Pogue, et 
al.; Yalavarthy, Lynch, et al.). This last step has a number of challenges. In general, the 
inversion of the matrix and the inverse problem solution is ill-posed because large 
changes in the model tend to produce only small changes in measurable parameters (real 
experimental data). Moreover, with the number of pixels larger than the number of 
measurements, the problem is underdetermined (Boas et al.). Both problems can be 
resolved with additional parameters known as penalty terms. These terms are added to 
the least-squares equation restricting the solution and enhancing the image. Basic 
Tikhonov zero-order regularization (Correia et al.) and more complex functions such as 
truncated singular value decomposition (TSVD) have been implemented to improve the 
image quality (Schweiger, Arridge and Nissila; Gaudette et al.; Yalavarthy, Lynch, et al.). 
The search for the appropriate regularization is in progress in the field of image 
reconstruction. For detailed information on light transport modeling and image 
processing, the reader is referred to several extensive reviews on the subject (Arridge and 
Hebden; Gibson, Hebden and Arridge). The details of the light modeling and 
reconstruction algorithm implemented on this thesis will be described on each chapter as 
needed. 
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1.3.1 Optical Imaging Platforms 
 This section covers the basic principles of some optical imaging techniques such as 
planar imaging; diffuse optical spectroscopy, and diffuse optical imaging, with and 
without the use of exogenous contrast reagents. The roles of these techniques in clinical 
detection, staging, and treatment monitoring of tumors are briefly described. 
1.3.1.1 Planar Imaging 
 Over the past two decades, optical molecular imaging have benefited from the rapid 
advances in light sources, detectors, and mathematical modeling techniques. 
Fluorescence planar imaging is the simplest optical method and it is akin to flash 
photography. The method is fast and affordable and data analysis is straight forward. 
The light source required for planar imaging can be as simple as a single white light or a 
bundle of optical fibers equipped with optical switches (Ntziachristos, Turner, et al.). In 
its simplest form, appropriate filters are used to select the desired excitation wavelengths 
from a broad spectrum of light source such as bright light bulbs. More recent versions 
use CW lasers or light emitting diodes (LEDs) as the light source to provide higher 
power for deep tissue imaging. The ensuing fluorescence is captured with a charge-
coupled device (CCD) camera, the signal is recorded temporally on a computer and 
displayed on a monitor in near real-time. Planar imaging systems are mostly used to 
obtain two-dimensional images of tissue in reflectance (epi-fluorescence) or transmission 
geometry. In transmission geometry, the detector is placed on the opposite side of the 
excitation source. Most of the commercially available small animal planar imagers utilize 
the epi-fluorescence mode because of its simplicity and to overcome problems with 
attenuation of light in thick tissue. 
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 Normally, the images are generated from the recorded intensity of the emitted light 
in every pixel of the region-of-interest (ROI). Such images show the location of the 
target fluorescent molecular probe in tissue. However, the images are surface-weighted, 
resulting in the loss of quantitative accuracy, depth information and poor spatial 
resolution caused by scattering of the emitted light. Improvement of the reflectance and 
trans-illumination planar imaging methods can be achieved with data normalization 
approach (Ntziachristos, Turner, et al.). In this technique, the excitation and emission 
light intensities are acquired sequentially by switching the interference filter between 
excitation and emission scans. The normalized image is generated by simply dividing the 
emission light intensity by the excitation light intensity. The phantom and in vivo studies 
showed that the normalized data improved the image quality and accuracy as well as the 
depth sensitivity over non-normalized method (Hyde et al.; Ntziachristos, Bremer and 
Weissleder; Ntziachristos and Weissleder "Experimental Three-Dimensional 
Fluorescence Reconstruction of Diffuse Media by Use of a Normalized Born 
Approximation"). 
 Further improvement in the depth resolution of planar imaging can be achieved by 
introducing phase profilometry technique into the system. The basic principle of phase 
surface profile characterization (profilometry) is similar to that of tomographic imaging 
systems. Both techniques have depth-sectioning ability from the recovered depth 
information of the imaging object. Implementation of the phase information recovered 
from the reflected light for 3D image reconstruction was first implemented by Gabor et 
al. (Gabor). In this method, a spatially modulated intensity sine wave is projected onto 
the object and imaged with a camera from an offset position (Srinivasan, Liu and 
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Halioua). The longitudinal distance between a reference plane and the object surface is 
extracted from the phase distribution at each pixel from multiple sine waves to provide 
the depth information (Gioux et al.). An alternative approach is to perform a fast Fourier 
transform using a single intensity sine wave (Takeda and Mutoh). In a typical 
arrangement, a light source (profilometer laser) and a detector (profilometer camera) are 
used to create a phase shift. The laser and camera can be synchronized by tilting the 
platform to further enhance light penetration depth (Gioux et al.). Overall, profilometry 
and triangulation methods produce good quality 3D images but this comes at the 
expense of complex hardware and longer processing time. From instrumentation and 
data analysis point of view, these techniques are closer to tomographic systems than to 
conventional planar imagers. 
1.3.1.2 Diffuse Optical Spectroscopy 
 Diffuse Optical Spectroscopy (DOS) is the most established optical imaging 
technique for clinical applications. DOS has been widely used to obtain spectrally 
dependent functional and structural information by extracting absorption and scattering 
coefficients associated with concentration changes in endogenous and exogenous 
fluorophores (Ramanujam et al.; Richards-Kortum and Sevick-Muraca; Sokolov, Follen 
and Richards-Kortum; Tromberg et al.; Kukreti, Cerussi, Tanamai, et al.; Vishwanath, 
Klein, et al.). Measurement of hemoglobin absorption in vivo is one of the central 
approaches in DOS. The absorption spectra of oxy- and deoxy- hemoglobin state differ 
significantly and the ratio between the two states in tissues is highly conserved. The 
changes in oxy- and deoxy-hemoglobin concentration often indicate tissue abnormality 
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and are frequently used to identify physiological problems and follow effects of therapy. 
In a typical setting, DOS systems are mostly composed of a handheld probe employing a 
flexible fiber based source-detector configuration. Among a variety of DOS techniques, 
double-differential spectroscopic analysis and diffuse reflectance spectroscopy are the 
most common. Double-differential spectroscopic analysis of tissue’s absorption and 
scattering spectra from 650nm to 1000nm has been applied to discriminate normal from 
cancerous breast tissues. In this method, subtracting the major absorbers' spectral 
components of normal from cancerous tissues provides patient-specific molecular 
signature of the tumor (Kukreti, Cerussi, Tromberg, et al.; Kukreti, Cerussi, Tanamai, et 
al.).  
 The feasibility of diagnosing tumors and using diffuse reflectance spectroscopy to 
monitor cancer therapy response by quantifying the associated physiological and 
morphological changes has also been demonstrated (Vishwanath, Yuan, et al.). To 
accomplish this goal, the authors extracted the concentration of oxy- and deoxy-
hemoglobin, and scattering coefficient by applying inverse Monte Carlo model of light 
transport to diffuse reflectance spectra collected from tumor bearing mice models 
(Vishwanath, Yuan, et al.). A significant increase in the concentration of oxy-hemoglobin 
was observed in doxorubicin treated animals, which implies that diffuse reflectance 
spectroscopy can be used to monitor treatment response non-invasively. 
 Palmer et al. utilized hemoglobin based DOS to study physiological changes in 
response to combinational therapy using hyperthermia and liposomal doxorubicin in a 
murine model (Palmer et al.). Both diffuse reflectance and fluorescence spectroscopic 
measurements were performed, allowing multiparametric quantification of optical 
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properties of tissues and fluorescence of the drug doxorubicin. The study demonstrated 
that the total hemoglobin saturation increased after treatment. In a human study, Cerussi 
et al. used DOS to evaluate a patient suffering from infiltrating ductal carcinoma (Cerussi 
et al.). Here, the patient received a neoadjuvant chemotherapy consisting of 
anthracyclines and bevacizumab treatments. Instead of directly comparing the tumor 
water content and deoxy-hemoglobin concentration, a composite tissue optical index, 
defined as ([deoxy-hemoglobin]x[water])/[lipids] was used to evaluate responses. A 
decrease of ~50% in the index was found in the course of the chemotherapy, indicating 
high sensitivity of the index to tumors responding to treatment.  
 Overall, the results obtained by different research groups demonstrate the capability 
of DOS to dynamically monitor tumor-associated physiological and morphological 
changes non-invasively and use the information to identify patients’ response, or lack 
thereof, to chemotherapy (Choe, Corlu, et al.; Choe, Konecky, et al.; Kukreti, Cerussi, 
Tromberg, et al.; Kukreti, Cerussi, Tanamai, et al.). 
1.3.1.3 Diffuse Optical Imaging 
 Diffuse optical imaging (DOI) method is similar to DOS, but it is more complex 
due to the use of multiple source-detector combinations for data acquisition and image 
reconstruction. DOI has been used successfully in a quantitative study of the 
pharmacokinetics and pharmacodynamics of diagnostic and therapeutic agent, which is 
also the basis for this thesis work (S. Patwardhan et al.; S. V. Patwardhan, S. Bloch, et al.; 
Patwardhan and Culver; Ntziachristos, Tung, et al.; Choe, Konecky, et al.; Hebden, 
Arridge and Delpy).  
    
 
29 
 Diffuse optical tomography (DOT) method produce three-dimensional images of 
tissue by combining measurements from multiple sources and detectors with light 
diffusion modeling techniques for depth localization (Vo-Dinh; Gibson, Hebden and 
Arridge; Wang and Wu; Hebden, Arridge and Delpy). A variant of DOI systems, 
fluorescence molecular tomography (FMT), acquires excitation and emission light 
intensity profiles sequentially with interference filter switching between two scans 
(Ntziachristos, Bremer and Weissleder; Ntziachristos, Tung, et al.; Pogue, Gibbs, et al.). 
A CCD camera is generally used as detector in this technique. The sequentially acquired 
excitation and emission light intensities are used to generate normalized data-set from 
the emission light intensity profile divided by the excitation light for volumetric 
reconstruction of the fluorescence distribution. Using this approach, Patwardhan et al. 
developed an FMT system capable of whole-body small animal imaging within a few 
minutes (S. Patwardhan et al.). The system was successfully used to quantify the 
biodistribution of targeted fluorescent molecular probes in mice bearing subcutaneously 
implanted human breast carcinoma. 
 In addition to reporting the fluorescence intensity, optical imaging systems can be 
modified to quantify fluorescence lifetime. Fluorescence lifetime is an intrinsic property 
of endogenous and exogenous fluorophores that relates to the average time a 
fluorophore remains in the excited state before light emission. Advances in laser 
technology and instrumentation have led to the development of time-resolved imaging 
techniques for whole-body imaging of cancer in small animal. This trend has aided the 
growing interest in developing new FLI systems for tumor imaging (Berezin, Lee, Akers, 
Guo, et al.; Nothdurft et al.; Bloch et al.; Berezin and Achilefu). 
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 An important advantage of fluorescence lifetime contrast over fluorescence intensity 
measurements lies in its less dependence on the fluorophore concentration. However, it 
is generally sensitive to changes in the local tissue environment such as pH, temperature, 
and presence of fluorescence quenchers (Berezin, Lee, Akers, Guo, et al.; Nothdurft et 
al.; Bloch et al.; Berezin, Lee, Akers, Nikiforovich, et al.). This sensitivity to differences 
in tissue composition and biochemistry has been used to differentiate cancerous from 
normal tissues by fluorescence lifetime imaging (FLI) (Berezin, Lee, Akers, Guo, et al.; 
Nothdurft et al.; Bloch et al.; Berezin and Achilefu). Cubeddu et al. applied time-domain 
imaging to localize tumors after fluorescent hematoporphyrin derivative (HpD) uptake 
used for photodynamic therapy (Cubeddu, Canti, Taroni, et al.; Cubeddu, Canti, Pifferi, 
et al.). The authors treated L1210 leukemia and fibrosarcoma tumors with 
hematoporphyrin derivative and observed that the fluorescence lifetime were longer in 
both tumors than in the surrounding normal tissue. This group also demonstrated that 
FLI can discriminate between normal and basal cell carcinoma in human skin based on 
the lifetime differences between protoporphrin IX and normal tissue autofluorescence 
(Andersson-Engels et al.). 
 Reynolds et al. used frequency domain for lifetime sensitive detection of molecular 
probes.  They extracted and differentiated NIR contrast agents based on their lifetime 
differences in tissue mimicking phantoms (Reynolds et al.). The ability to measure 
multiple fluorescence lifetimes from several fluorescent probes in relatively narrow 
lifetime range (0.5-1.2 ns) demonstrated the potential of fluorescence lifetime imaging in 
differentiating cancerous from normal tissues. Most in vivo lifetime imaging studies were 
confined to specialized laboratories until the commercialization of a time-domain 
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lifetime imaging system. Bloch et al. demonstrated the feasibility of using receptor-
targeted NIR fluorescence molecular probe (cypate-GRD) for non-invasive whole-body 
fluorescence lifetime imaging with this commercial system (Bloch et al.). The study 
showed selective localization of the tumor based on the probe’s lifetime properties. 
Further tissue analysis showed that the fluorescence lifetime of the molecular probe was 
1.03 ns in tumor and 0.83 ns in the surrounding tissue. Although the lifetime changes 
appear to be small, modern FLI systems are capable of resolving 0.1 ns lifetimes, making 
it possible to potentially detect small but significant physiological changes in tumors. 
 The development of fluorescence lifetime tomography has further enabled 
improved temporal resolution and accurate tissue localization up to 1 cm depth of 
targeted tumor using fluorescent molecular probes. Nothdurft et al. developed a 
fluorescence lifetime tomography system that quantitatively resolves fluorescence 
lifetimes within the narrow range 0.35 ns and 1.35 ns in vivo (Nothdurft et al.).  In this 
work, targeted exogenous NIR optical probe, cypate-cyclic[RGDfk], was injected into a 
mammary carcinoma mouse model and the fluorescence lifetime map of whole animal 
recorded. The tumor was quantitatively differentiated from the surrounding tissue based 
on the fluorescence lifetime and intensity maps.  
 Fluorescence lifetime imaging has also enabled imaging of multiple fluorophores 
with similar absorption and emission spectra but different lifetimes to provide 
simultaneous information about specific molecular processes without the need for 
spectral deconvolution of each fluorophore. Reynolds et al. [69], Akers et al. (Akers et 
al.) and Raymond et al. (Raymond et al.) were able to recover and separate the 
distribution of two or/and three NIR fluorescent probes that localized in different 
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organs of mice based on difference of their lifetimes. Their findings suggest that the 
fluorescence lifetime of different molecular probes can be multiplexed to monitor a 
variety of molecular interactions through a careful design of NIR fluorescent probes to 
exhibit lifetime shifts upon target binding. However, one should keep in mind that the 
difference between individual fluorescence lifetimes must surpass the temporal 
resolution of the instrument (currently ~100 ps for tomographic systems) to realize 
lifetime multiplexing. 
 Overall, optical molecular imaging has the potential to become a powerful and 
practical tool for a wide array of applications such as noninvasive early detection, image-
guided biopsies and intraoperative procedures, and therapeutic monitoring of cancer. 
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Chapter 2 
 
Video-rate Fluorescence Diffuse Optical 
Tomography for in vivo Sentinel Lymph 
Node Imaging 
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2.1 Introduction 
 
 Sentinel lymph node biopsy (SLNB) is the current standard procedure used for 
prognostic staging of cancers and therapeutic guidance. SLNB is a minimally-invasive 
procedure that involves the removal of sentinel nodes (the first lymph nodes that receive 
drainage from the primary tumor) for nodal staging. The location of sentinel lymph 
nodes (SLNs) is routinely determined by injecting radioactive lymphophilic tracer dye 
intra-operatively around the tumor region. The lymphophilic tracer is commonly 
composed of a radioactive colloid and/or optical contrast methylene blue for visual 
guidance (Tuttle et al.; Hojo et al.). Due to safety issues, a non-invasive and non-ionizing 
method for imaging of metastatic lymph nodes and lymphangiogenesis would be 
preferred. Fluorescence diffuse optical tomography (DOT) is an emerging deep tissue (> 
3 mm) imaging technique that has great potential as an alternative to radioactive tracer 
analysis for noninvasive detection and imaging of the sentinel lymph node. While 
fluorescence DOT often operates on the time scales of minutes to hours, the method 
also has the potential for imaging at higher speeds above the respiratory and cardiac 
fluctuations, allowing it to capture pharmacokinetics and pharmacodynamics of 
diagnostic and therapeutic agents. 
 Currently, most fluorescence diffuse optical tomography systems are CCD camera-
based systems that scan at relatively slow speeds (i.e., frame rates < 0.01 Hz). The slow 
speed is due in part to the method by which ratio-metric data is acquired. Excitation and 
emission light intensity profiles are imaged consecutively, which requires that an 
interference filter for blocking the excitation light to be mechanically inserted between 
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the two scans (Ntziachristos and Weissleder "Charge-Coupled-Device Based Scanner for 
Tomography of Fluorescent near-Infrared Probes in Turbid Media"; S. V. Patwardhan, 
S. R. Bloch, et al.; Patwardhan and Culver). Comparison of sequentially acquired 
excitation and emission light intensities improves image quality through the generation 
of a normalized ratio-metric data-set (Patwardhan and Culver; Ntziachristos, Turner, et 
al.). However, the mechanical requirements of sequential scanning slow data collection 
and pose a challenge for real-time imaging. Alternatively, DOT systems developed to 
image functional absorption contrast have used time- or frequency-encoding of the 
illumination with broad spectral detection to image fast activities (> 10 Hz) within the 
human brain. This style of DOT system replaces the CCD-camera acquisition with 
multiple photodiode detectors in order to take advantage of the high dynamic range and 
high speed of avalanche photodiodes (APDs) (Culver, Siegel, et al.; Franceschini and 
Boas; Zeff et al.). However, the discrete detector DOT approach has not yet been 
applied to ratio-metric data for fluorescence DOT. 
 Herein, we aim to improve upon current fluorescence DOT platforms by 
developing a system with expanded dynamic range and faster data acquisition rates. The 
video-rate, fiber-based fluorescence DOT system design is built upon a previously 
published APD-based platform for high-speed DOT (Zeff et al.). 
 The source-detector grid is designed as a contact probe to pre-operatively identify 
SLNs near the tumor region after administration of a fluorescent contrast agent. Biopsy 
of SLNs would follow intra-operatively to enable further histological evaluation for the 
presence of metastatic cells. These studies with a non-specific, but approved, contrast 
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agent ICG will set the stage for future work with more specific targeted contrast agents 
that fluoresce/activate in the presence of metastatic cells. 
 Fiber-based, video-rate fluorescence DOT could additionally improve the flexibility 
of imaging by adapting to varying tissue curvatures and performing simultaneous 
multiple point illumination and collection, thus increasing the imaging frame rate. 
 In this chapter, I demonstrate the feasibility of in vivo imaging of the dynamics of 
dye accumulation in the region of the sentinel lymph nodes and quantify the accuracy of 
depth localization and sensitivity in tissue-simulating phantoms. These results 
demonstrate that fiber-based, video-rate fluorescence DOT is a practical and powerful 
tool that is well suited to a wide array of potential imaging applications, ranging from 
sentinel lymph node mapping to monitoring cancer therapy progression. 
2.2 Methods 
 The generation of ratio-metric (fluorescence-to-reference) data for fluorescence 
DOT reconstructions has previously relied on sequentially acquired measurements where 
the source laser is kept at the excitation frequency while a band-pass filter in front of the 
detector alternates between allowing through excitation and emission (fluorescent) light. 
The detected excitation light is then used as a reference to normalize the measured 
fluorescence. The acquisition of such ratio-metric data allows reconstructions using the 
normalized Born approximation, which can be implemented to quantify fluorochrome 
distribution. However, while the use of an excitation reference is customary, it is not 
required. The assumption that light at the excitation wavelength acts as a good reference 
inherently assumes similar optical properties at the two wavelengths. And, if this 
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assumption is made, there is no reason why light at the fluorescence wavelength could 
not be used as a reference. With a CCD-based system, this would be impractical, as there 
would be no way to determine the difference between the fluorescent and reference light 
at the same wavelength. However, with APD-based detection, high speed allows the use 
of frequency-encoding regimens to separate out contributions from different sources. 
With this encoding scheme, there is no longer any need for the hardware-based 
temporal-encoding of switching a filter in and out of the light beam. This paradigm is the 
basis for the system presented here. 
 The fiber-based, video-rate fluorescence DOT system is composed of an alternating 
grid of 12 sources and 13 detectors (Figure 2.1). The video-rate fluorescence DOT 
system uses multimode fiber to carry light from the source box (Figure 2.1 A.1) to the 
imaging pad (Figure 2.1 A.2) and then to the detector box (Figure 2.1 A.3).  
 
 
 
Figure 2.1: Fiber-based, video-rate fluorescence DOT system setup (a) The video-rate 
fluorescence DOT prototype. Fibers carry light from the source box (1) to the imaging 
pad (2) then to APDs in two detector boxes (3). The detected signals are digitized by an 
ADC recording unit (4). (b) A close-up of a 5x5 fiber array. 
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 The source channels contain 785 nm (Thorlabs DL7140-201S) (3.5 mW) and 830 
nm (Thorlabs HL8325G) (0.25 mW) laser diodes, with dedicated laser diode drivers and 
control lines for each source, allowing flexible software configurable source encoding 
(frequency- and time-encoding) (Figure 2.2 A). Light from the sources is coupled into 
2.5 mm diameter fiber bundles. The detection channels use optically-filtered discrete 
avalanche photodiodes (Hamamatsu C5460-01) digitized with dedicated 24-bit analog-
to-digital converters (MOTU HD 192). A narrowband optical filter with center 
wavelength 830 +/- 10 nm (CVI) and an out-of-band rejection of OD4 separates the 
excitation light from fluorescent and reference signals. An aspheric lens is used to 
collimate the light in order to optimize the blocking of excitation light by the 
narrowband interference filter and enhance fluorescent signal detection. This design 
provides high instantaneous dynamic range (106) and cross-talk rejection (10-6), so that 
light levels can be detected over many orders of magnitude. With this scheme, we 
acquire frequency-encoded fluorescence emission and reference transmission light levels 
simultaneously at each detector through the individual interference filters optimized for 
fluorescence emission (Figure 2.2A). All data are acquired at a frame rate of 30 Hz. A 
total of 108 measurements from source-detector-pairs (also known as optode-pairs) 
representing the 1st, 2nd, and 3rd nearest-neighbors are used for image reconstruction. 
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Figure 2.2: Schematic of the video-rate fluorescence DOT hardware. (A) Schematic 
demonstrating frequency-encoding of 830 nm and 785 nm laser diode sources. Both 
reference and excitation light (at distinct frequencies) are incident on the tissue. Light 
exiting consists of reference, excitation, and emission (fluorescent) light. After 
collimation, the light is passed through a narrow band optical filter (F) to block the 
excitation light (785 nm). The resulting detected light, a sum of the reference 
transmission (I2) and fluorescence emission (I3), is simultaneously detected by a single 
detector. (B) A Fourier transform of the sum of I2 and I3 provides identification of 
transmission and emission signals from a single detector. 
2.2.1 Ratio-metric Reconstruction 
 The reference transmission and fluorescent emission light intensities acquired 
concurrently at each detector (Figure. 2.2B) are used to generate ratio-metric data of 
fluorescence   divided by reference transmission. The data are then reconstructed using 
the normalized Born approach to correct for tissue and illumination inhomogeneities, 
which is written in discrete notation as y=Ax with the following definitions (Zeff et al.). 
 In the Normalized Born approach: 𝑦! =   !!"# !!(!),!!(!),!!"#!!"# !!(!),!!(!),!!"#  . When the bleed-
through of the filter is accounted for then the Normalized Born approach becomes: 
𝑦! =   𝜙!"# 𝑟!(!), 𝑟!(!), 𝜆!"# − 𝜙!"##$%!!"#$!(𝑟!(!), 𝑟!(!))𝜙!"# 𝑟!(!), 𝑟!(!), 𝜆!"#  
 The ratio-metric data (y) is generated by measuring the fluorescence light intensity 
profile 𝜙!"# 𝑟!(!), 𝑟!(!), 𝜆!"#  at emission wavelength,  𝜆!"# , and the reference 
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transmission light intensity profile, 𝜙!"# 𝑟!(!), 𝑟!(!), 𝜆!"# , at the reference wavelength , 𝜆!"# . The ith source-detector measurement (yi) is associated with source (rs(i)) and 
detector (rd(i)) locations.  
 The bleed-through measurement is made in the absence of a fluorescing agent and 
measures the amount of light leakage through the filter. It is determined by: 𝜙!"##$%!!"#$! 𝑟! ! , 𝑟! ! = 𝛼×𝜙!"# 𝑟! ! , 𝜆!"# =   𝛼!"#$%&! ! ×𝑅×𝜙!"# 𝑟! ! , 𝜆!"# ; 𝑤ℎ𝑒𝑟𝑒  𝑅 = !!"# !! ! ,!!"#!!"# !! ! ,!!"# ;   𝛼 captures the optical density of the filter. In this fiber-based fluorescence DOT system 
there are individual detectors and sources, and the sources have separate lasers for both 
reference and excitation. Therefore, the 𝛼 is calculated separately for each source-
detector pairs. To calculate the bleed-through specific to an imaging study, we derived an 
estimate of the bleed through of 𝜙!"# based on 𝜙!"# . Experimentally determined 
conversion factors (𝛼 and R) are used to account for the difference in power level 
between the excitation and reference lasers. R is measured using a power meter at source 
fiber tips of each sources and 𝛼!"#$%&!(!)  is the excitation light measured with and without 
filter,  𝜙!"# 𝑟! ! , 𝜆!"# , for each detectors at the excitation wavelength (𝜆!"!) of 785 nm. 
 The sensitivity matrix (𝐴!,!) is created using the analytic solutions for photon density 
in the semi-infinite geometry to obtain the influence of a particular voxel j on every 
source and detector measurement i. 
𝐴!,! = − 𝑠!𝑣ℎ!𝐷!   𝐺 𝑟! ! , 𝑟! , 𝜆!"# 𝐺 𝑟! , 𝑟! ! , 𝜆!"#𝐺 𝑟! ! , 𝑟! , 𝜆!"# ;   𝑥!  !𝜕𝑁! 
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 The So is calibration factor while h
3 represents the voxel volume. The Do and v are 
the diffusion coefficient and speed of light in the medium. The two-point Green’s 
function, G, models light transport for the given boundary condition. Optical properties 
at the reference wavelength of µa = 0.1 cm
-1 and µs' = 10 cm
-1 were used to model the 
optical properties of rat and chicken muscles for both in vivo and phantom studies 
(Marquez et al.; Nilsson, Berg and Andersson-Engels; Cheong, Prahl and Welch). In this 
case, a semi-infinite geometry is implemented. 𝑥!   is the jth recovered image voxel that 
contains the fluorescence yield,  𝜕𝑁! , obtained using a Moore-Penrose generalized inverse 
(Culver, Siegel, et al.). 
2.2.2 System Performance Analysis 
2.2.2.1 Design of Simulation Studies  
 The system's depth sensitivity was first evaluated with simulation studies before 
proceeding to phantom and in vivo studies. To evaluate the depth sensitivity, 1x1x1 mm 
fluorescent targets mimicking labeled sentinel lymph nodes were simulated as 
perturbations in homogeneous medium with the addition of 1% biological measurement 
noise at different depths. A sensitivity matrix with a simulated grid of 12 sources and 13 
detectors was implemented for image reconstruction. To evaluate a potential clinical 
application, sentinel lymph node mapping for cancer staging, we reconstructed simulated 
fluorescent lymph nodes at various depths (3, 5, 8, 11, 15,) with simulated 1% noise 
(Figure. 2.3A). The reconstructed images suggest that the video-rate fluorescence DOT 
will have depth-sectioning capabilities with accurate depth localization down to 15mm 
confirming its potential for clinical application (Figure 2.3B). The resolution of the 
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system was tested by using the simulated 1x1x1 mm target at different depths. The size 
of the reconstructed perturbation is measured with the full width at half maximum 
(FWHM) of each target's point-spread function (PSF). We observe a broadening of the 
response with depth (Figure 2.3C). 
 
Figure 2.3: Evaluations of imaging depth sensitivity. To evaluate the depth sensitivity of 
the reflectance fluorescence DOT imaging array (Figure 2.1c), we reconstructed images 
from simulated data for targets at different depths. Two-dimensional slices through a 
volume show a cross-sectional view. Targets of 0.125 mL in volume (A) at the depths of 
3, 5, 8, 11, 15 mm (left to right) were reconstructed. (B) Targets are all clearly visible 
even in the presence of simulated measurement noise (1%). (C) Point-spread function 
analysis using a simulated image reconstruction. Half-maximum contours of responses 
for different depths are shown. 
2.2.2.2 Design of Phantom Studies 
 To evaluate the performance of the system, different concentrations of ICG targets 
in 3 mm diameter plastic tubes were prepared and embedded at 7 mm depth in a breast 
tissue mimicking phantom with µa = 0.1 cm-1 and µ's = 10 cm-1 (Figure 2.4A). The 
breast tissue simulating phantom was constructed by mixing 1% Intralipid solution with 
Black India ink to obtain the appropriate absorption and scattering properties (Flock et 
al.). The absorption and reduced scattering coefficients are chosen based on previously 
published values of rats and chicken breast optical properties (AN. Bashkatov et al.; 
Cheong, Prahl and Welch; Nilsson, Berg and Andersson-Engels; Marquez et al.). The 
targets contained solutions of indocyanine green (Sigma-Aldrich, St Louis, MO) in 
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concentrations ranging from 1 nM to 1 µM. The averaged values from regions-of-
interest (ROIs) of the reconstructed image were compared to known concentrations to 
evaluate the sensitivity and linear response of the system. 
 Analysis of the system’s sensitivity as a function of depth was performed by 
submerging a 3 mm diameter plastic tube of 4 µM concentration in a tissue-mimicking 
phantom. Starting at a depth of 5.5 mm, the tube was moved in 1.5 mm increments via a 
vertical stage until the middle of the tube reached a depth of 13.5 mm. The depth 
localization accuracy of the fluorescent target and sensitivity were calculated by averaging 
the intensity of the tube ROI and computing the center-of-mass for the different depths 
acquired. 
2.2.3 Probe Dynamics Measurement in Sentinel Lymph 
Node Imaging 
2.2.3.1 Design of in vivo Studies 
 We conducted a non-invasive preclinical study of fluorescent sentinel lymph node 
mapping in rats (n=5) with our fiber-based, video-rate fluorescence DOT system. The 
hair was shaved from the axillary region prior to imaging. In order to test the 
translational feasibility of the system to humans (which will require imaging at depths > 
1 cm), we also conducted an experiment mimicking a deeper imaging scenario than 
would normally be available in a rat by inserting 8-10 mm of chicken breast tissue 
between the rat chest wall and the imaging pad (Figure 2.4B). Imaging through 8-10 mm 
chicken breast increased the depth of the SLNs to 10-12 mm, which is deeper than the 
typical 2 mm where the SLNs are normally located below the skin surface in rats. 
Control images were acquired for 1 minute prior to administration of the ICG, and the 
    
 
44 
dynamics of the injection in the axillary region were monitored for 10 minutes 
continuously. 
 Animal handling was performed according to the guidelines approved by the 
Washington University School of Medicine Animal Studies Committee for humane care 
and use of laboratory animals. For in vivo imaging, 50 µL of 100 µM ICG was injected 
intradermally in the left forepaw of 200-250 g female Sprague Dawley rats (HSD, 
Indianapolis, IN) after giving a mixture of ketamine (85 mg/kg) and xylazine (15 mg/kg) 
for anesthesia. After imaging, rats were then euthanized with an overdose of 
pentobarbital solution (150 mg/kg, IP) and the lymph nodes were then resected for 
verification of ICG uptake. 
 For reference and verification of ex vivo ICG uptake by the lymph nodes, 
superficial fluorescence images were acquired without the layers of chicken breast using 
the Pearl near-infrared (NIR) fluorescence imaging system (LiCor Biosciences, Lincoln, 
NE). 
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Figure 2.4: Schematic of the video-rate fluorescence DOT experimental setup. (A) 
Schematic of my experimental setup with an imaging array and a 3 mm ICG tube 
embedded in a tissue-mimicking phantom. (B) Schematic of the placement of the fiber 
array on a preclinical animal model using an 8-10 mm thick chicken breast to simulate a 
deep tissue imaging situation. 
2.3 Results 
2.3.1 System Performance Analysis with Phantom Studies 
 The Fourier transform of a measurement from a single detector illustrates the use of 
frequency-encoding to separate the emission and reference measurements acquired 
simultaneously (Figure 2.2B). Following frequency-decoding, the intensities of both 
reference transmission and emission were retrieved. The data was then used to generate 
volumetric reconstructions of the fluorescence distribution. The reconstructed images 
from various depths suggest that the newly developed video-rate fluorescence DOT 
system has the capability to accurately section depths up to 13.5 mm (Figure 2.5B). The 
resolution of the system was tested with simulated data for 1×1×1 mm phantom targets 
at different depths (Figure 2.3C). The center-of-masses (COMs) of the reconstructed 
fluorescence tubes (Figure 2.5B) were computed by averaging the fluorescence intensity 
values for each experimental depth. The linear relationship between the experimental 
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and the computed COMs demonstrate the depth localization accuracy up to 13.5 mm 
(Figure 2.5C). The sensitivity as a function of depth was computed by taking the mean 
fluorescence intensity of the regions-of-interest from reconstructed image for the 
different depths acquired (Figure 2.5D). The data demonstrate that the signal intensity 
drops exponentially with depth, as expected. 
 The relationship between the true dye concentration and the reconstructed voxel 
value (arbitrary units), is shown in Figure 2.5E. The graph confirms the high dynamic 
range and linear response of our system to varying ICG concentrations as measured by 
the resulting fluorescent yield from 1 nM to 1 µM. Values from this phantom analysis are 
used to generate a calibration factor for our in vivo studies. 
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Figure 2.5: System sensitivity analysis with phantom studies. (A) Schematic of our 
experimental setup with an imaging array and a 3 mm ICG tube embedded in a tissue 
mimicking phantom. (B) Vertical x-z and y-z slices of reconstructed experimental data 
from a fluorescent 3 mm tube target whose center of mass is located at 7.5 mm, 10.5 
mm, and 13.5 mm depths. The system accurately reconstructs the tube shape with some 
artifact at the optode positions. (C) Evaluation of the depth localization accuracy of a 
phantom target. The system has accurate localization from 6 to 13.5 mm. (D) Sensitivity 
vs. depth. The data demonstrate that the signal intensity falls off exponentially with 
depth. (E) The relation between the raw reconstructed value and the true concentration 
of the dye was characterized by titration of ICG from 1 nM to 1 uM concentrations in a 
3 mm tube. 
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2.3.2 In vivo Imaging of the Uptake of the dye into SLNs 
 We performed a pre-clinical in vivo study to evaluate the feasibility of imaging 
sentinel lymph nodes in rats noninvasively. ICG was injected intradermally into the 
forepaw and the axillary region was imaged with DOT. The DOT images of fluorescent 
lymph dynamics shown at 2 mm were obtained following injection of the ICG (Figure 
2.6A). Representative dynamics of fluorescent lymphatic fluid accumulation is obtained 
from a volume of about 30 mm3 from the region of the sentinel lymph node of the 
injection site (Figure 2.6B). The mean of the background pixels shows no fluctuation 
associated with the dynamics of fluorescent dye. 
 Reflectance fluorescence images were captured using the Pearl NIR fluorescence 
imaging system before sacrificing the animal to confirm the DOT results (Figure 2.6C). 
Reflectance fluorescence images acquired after euthanasia and removal of overlying skin 
further confirmed ICG uptake by the lymph node imaged by DOT (inset on Figure 
2.6D).   
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Figure 2.6: Shallow imaging of lymph dynamics. (A) DOT images of the fluorescence 
dynamics at 2 mm depth in a rat following injection of ICG into the left forepaw. (B) 
Time traces of the dynamics of ICG accumulation in the region of the sentinel lymph 
node (for comparison the mean background signal is shown). (C) Reflectance 
fluorescent imaging of the sentinel lymph node region demonstrating fluorescence from 
the injection site (paws) and the lymph vessels leading to axillary lymph nodes (arrow). 
(D) Reflectance fluorescent image of the rat after euthanasia and removal of overlying 
skin. Inset: fluorescence from ex vivo imaging shows ICG uptake in the lymph nodes. 
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 We repeated the experiment with an increased imaging depth by inserting 8-10 mm 
of chicken breast between the rats (n=5) and the imaging pad. DOT images of 
fluorescent lymph dynamics were acquired and show that high quality imaging can be 
obtained even at increased depth (Figure 2.7A). Time courses of the SLN region as well 
as background pixels demonstrate the representative dynamics of fluorescent lymphatic 
fluid accumulation after the injection (in two individual rats Figure 2.7B and averaged 
over all five rats Figure 2.7C). The variability in the lymph dynamics and accumulation in 
the SLNs can be associated with inter- and intra-subject variability of the periodic 
expansion and contraction structures that surrounds the lymphatic vessels. The results 
demonstrate the potential of the video-rate fluorescence DOT system to image the in 
vivo dynamics of dye accumulation in SLNs. 
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Figure 2.7: Deep (> 10 mm) imaging of lymph dynamics. The video rate fluorescence 
DOT was used to image the SLN region in rats through 8-10 mm of chicken breast 
following ICG injection into the rat forepaw. (A) The dynamics in a slice at 11 mm 
depth from a DOT reconstruction. (B) Time traces of the dynamics (for 2 representative 
rats) of a region around the SLN and of the mean of all background pixels. (C) 
Dynamics of ICG accumulation averaged over 5 rats. 
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2.4 Discussion 
 Fiber-based, video-rate fluorescence DOT has the potential to become a powerful 
and practical tool for a broad array of imaging applications, ranging from sentinel lymph 
node mapping to monitoring cancer therapy progress. We demonstrated the feasibility of 
a 30 Hz APD-based fluorescence DOT system. Images of fluorescent targets in tissue 
mimicking phantoms were used to confirm the high dynamic range and linear response 
of the system and the accurate localization of targets in the range of depths from 5.5 to 
13.5 mm. As the optical properties used in our experiments are higher than those 
reported for human breast tissues we expect the depth sensitivity and dynamic range to 
be improved in human studies. 
 We also successfully demonstrated the in vivo capabilities of the system by 
noninvasively imaging the dynamics of ICG accumulation in a rat. Accumulated dye in 
the region of the sentinel lymph nodes was imaged to a depth of 10-12 mm over a 10 
minutes time course. These results demonstrate the potential for imaging the 
pharmacokinetics of fluorescent diagnostic and therapeutic agents. 
 Previous two-dimensional fluorescence reflectance imaging (FRI) has been used to 
image lymph nodes and the lymphatic systems in animal models and cancer patients 
(Frangioni et al.; Proulx et al.; Sharma, Wang, et al.; Sevick-Muraca et al.; Troyan et al.; 
Sampath, Wang and Sevick-Muraca; Sharma, Wendt, et al.). For instance, the lymph 
dynamics and lymph node images obtained after injection of ICG in breast cancer 
patients show the feasibility of implementing FRI for nodal staging (Sevick-Muraca et 
al.). The specificity of the FRI method was further evaluated with an intraoperative FRI 
system by localizing the same SLNs as lymphoscintigraphy in breast cancer patients 
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(Troyan et al.). This particular FRI system is currently on clinical trials for intraoperative 
SLN mapping in cancer patients (Frangioni et al.; B. T. Lee et al.; Proulx et al.; Troyan et 
al.). While the FRI method is useful, its sensitivity declines quickly with imaging depth. 
 Three-dimensional DOT methods address several limitations of FRI and can 
potentially improve deep-tissue sensitivity, volumetric localization, resolution, and 
quantitative accuracy. For example, DOT approaches have been used in small animals to 
image whole bodies (Intes, Ntziachristos, et al.; S. V. Patwardhan, S. R. Bloch, et al.) and 
in humans to image breast (Pogue, Poplack, et al.; Culver, Choe, et al.; Choe, Corlu, et 
al.; Q. Zhang et al.) and brain (Joseph et al.; Austin et al.) tissues at depths of several 
centimeters. One limitation of our current system for application in humans is the 
limited field of view. The potential for an expanded system with up to 48 sources and 48 
detectors has been demonstrated for brain imaging (White et al.). A higher density 
imaging array could also potentially increase the resolution, particularly at the shallower 
depths (Culver, Ntziachristos, et al.). 
 Sentinel lymph node localization is currently performed by administering 
radiocolloids conjugated with blue dye for intraoperative guidance (Rzyman et al.). The 
potential of implementing other organic optical dyes such as fluorescein and indocyanine 
green has also been demonstrated in multiple clinical trials (Sampath, Wang and Sevick-
Muraca; Sevick-Muraca et al.; Troyan et al.; Hojo et al.; B. T. Lee et al.; Proulx et al.). 
Extensive research is still needed into targeted optical dyes. Fiber-based, video-rate 
fluorescence DOT aided with targeted optical dyes could have the potential to assess the 
cancer status of SLNs non-invasively in order to avoid unnecessary surgical procedures. 
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 Multimodal imaging with fluorescence DOT could also play an important role in the 
detection and imaging of sentinel lymph nodes for cancer management. DOT could be 
combined with, for example, nuclear imaging to improve the accuracy of DOT images 
during data processing and image reconstruction (Cao and Peter; A. Li et al.; Barber et 
al.). In addition to a standalone mode (and due to the flexibility of the fiber array 
geometries), video-rate fluorescence DOT also has the potential to be combined with 
handheld ultrasound (US) and/or photoacoustic tomography (PAT). Fibers assembled 
around the periphery of the PAT/US imaging head could provide many tracings through 
the PAT/US imaging volume. A similar approach wherein DOT is combined with 
ultrasound has been demonstrated feasible for imaging breast cancer (Q. Zhu et al.; 
Quing Zhu et al.). In these scenarios, the fluorescence molecular contrast of DOT would 
complement the high-resolution function and anatomical data of PAT and US. 
2.5 Conclusion 
 In this chapter, we have shown we have developed a fiber-based, video-rate 
fluorescence DOT system and demonstrated its potential for in vivo imaging. We have 
demonstrated that a 30 Hz APD-based DOT system can be operated in fluorescence 
mode. A fiber-based imaging array was used to image a fluorescent target within a tissue-
mimicking phantom and to exhibit our system’s high sensitivity. These results confirmed 
the high dynamic range and linear response of the system. We have also successfully 
demonstrated the capability of the system for sentinel lymph node mapping in rats. 
Further progress with this technology has the potential to provide a useful clinical tool 
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for a wide array of imaging applications, ranging from sentinel lymph node mapping to 
monitoring cancer therapy progress.  
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Chapter 3 
 
Multimodal Fluorescence Mediated 
Tomography and SPECT/CT for Small 
Animals Imaging 
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3.1 Introduction 
 Multimodal imaging strives to improve upon uni-modal imaging by combining 
multiple contrasts. For example, combining anatomical and molecular imaging (PET/CT 
and SPECT/CT) has provided an anatomical context for the detailed molecular 
information from the nuclear contrasts (Quing Zhu et al.; Alberini et al.; Even-Sapir, 
Keidar and Bar-Shalom). However, full fusion of the anatomical and molecular 
information is limited by the relatively weak connection between the different contrasts. 
Alternatively multiple molecular contrasts might be joined through specific links (S. 
Achilefu, Y. P. Ye, et al.; Zhang and Achilefu). For example, optical methods have 
unique activation contrast mechanisms, which are complementary to PET/SPECT 
information. The information available to both nuclear and optical contrasts can be 
harnessed directly using monomolecular multimodal imaging agent (MOMIA) (S. 
Achilefu, Y. P. Ye, et al.; Zhang and Achilefu). Imaging of MOMIA agents requires 
suitable instrumentation and algorithms. To combine optical data with PET/SPECT, 
optical contrasts can be imaged in three dimensions by diffuse optical tomography 
(DOT) (Z. R. Zhang et al.; Cao and Peter; Culver, Akers and Achilefu; C. Q. Li et al.). In 
this chapter, we demonstrate the feasibility of combining the previously reported fiber-
based, video-rate fluorescence mediated tomography (FMT) system (Metasebya Solomon 
et al.) with a preclinical NanoSPECT/CT platform (Bioscan, Inc.) for combined optical 
and nuclear imaging of dynamic events associated with lymphatic transport.  
The design and construction of a multimodal imaging platform presents a number 
of challenges. The first is integrating hardware such that each modality can function with 
minimal, or acceptable, interference from the others. Hardware integration requires 
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compatibility of all the parts for both platforms. The second challenge is spatial and 
temporal co-registration of information from the disparate reporting strategies under 
each modality. For instance, the distinct chemical and physical characteristics of 
traditional contrast agents might lead to different biodistribution and migration rates. 
MOMIAs are being developed to address these pharmacokinetic issues. Recent work has 
demonstrated the use of this approach for SPECT/optical (H. Lee et al.; Q. Zhang et 
al.), PET/Optical (Berezin, Guo, Teng, et al.; Zhang and Achilefu), and MRI/optical 
(Gulsen et al.; Guo et al.; Ntziachristos, Yodh, et al.) imaging. The last challenge is 
determining how to merge the anatomical or functional information from multiple 
technologies into a single imaging output. This is currently a subject of intensive 
research, though most of the work is focused on incorporating structural information 
from X-ray/CT (Ntziachristos, Yodh, et al.; Culver, Akers and Achilefu; Q. Zhang et al.) 
or MRI (Q. Zhang et al.; Gulsen et al.) with molecular imaging. Merging information 
that leverages the respective strengths of each modality would provide new insight into 
biological processes relevant to cancer diagnosis and therapy monitoring (S. Achilefu, Y. 
P. Ye, et al.; Culver, Akers and Achilefu).  
To address the instrument integration challenges, we took advantage of the 
flexibility of fiber arrays to provide a compact conduit of light to and from the animal so 
that the FMT imaging array could fit into the bore of the existing NanoSPECT/CT 
system without modifications. In addition, to facilitate integration of the nuclear and 
optical contrasts, we used a MOMIA based on a radiolabeled near-infrared dye 
synthesized in our laboratory (Zhang and Achilefu). 
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 Feasibility studies of simultaneous fluorescence and radioactive imaging were 
performed in tissue simulating phantoms and in vivo in rats. Accurate depth localization 
of the MOMIA targets was established to depths of up to 10 mm. Fluorescence and 
radioactivity from an injection of MOMIA into the forepaw region was imaged over 
time to follow the lymphatic dynamics. These studies were used to assess whether the 
proposed combined multimodal platform has the potential to become a practical tool for 
a broad array of imaging applications, ranging from early disease detection to monitoring 
progress of disease and therapies. 
3.2 Materials and Methods 
3.2.1 Fiber-based FMT Imaging System 
 DOT source and detector console: Laser diodes with a wavelength of 785 nm 
(Thorlabs DL7140-201S) (3.5 mW) and 830 nm (Thorlabs HL8325G) (1.5 mW) have 
dedicated drivers and control lines for each source to allow flexible software 
configurable source encoding (frequency- and time- encoding). The detection channels 
use optically-filtered discrete avalanche photodiodes (Hamamatsu C5460-01) digitized 
with dedicated 24-bit analog-to-digital converters (MOTU HD 192). The narrowband 
optical filters (CVI) have an 830 +/- 10 nm center wavelength and an out-of-band 
rejection of OD4, thus blocking the excitation light while passing the fluorescent and 
reference signals. An aspheric lens is used to collimate the light to optimize the blocking 
of excitation light by the narrowband interference filter and enhance fluorescent signal 
detection. With this scheme, we acquire frequency-encoded fluorescence emission and 
reference transmission (used to normalize the measured fluorescence) light levels 
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concurrently at each detector. This ratio-metric data allows DOT reconstructions using 
the normalized Born approximation, resulting in a map of quantified fluorochrome 
distribution. All data are acquired at a frame rate of 30 Hz. A total of 108 measurements 
from source-detector pairs representing the 1st, 2nd, and 3rd nearest-neighbors are used 
for image reconstruction. Further design elements and capabilities of the fiber-based, 
video-rate FMT are detailed in the previous chapter (Metasebya Solomon et al.). 
 DOT imaging fiber array: The imaging array is composed of a grid of alternating 
sources (12) and detectors (13). Light from the sources is coupled into 0.5 numerical 
aperture with 2.5 mm diameter fiber bundles made of borosilicate glass sheathed with 
lightweight silicone. The DOT imaging array composed of flexible silicone with right-
angle fibers is integrated with the NanoSPECT/CT system.  
3.2.2 SPECT/CT Acquisition 
 To test the compatibility of inserting the fiber-based FMT into nuclear platform, we 
used a NanoSPECT/CT platform (Bioscan, Inc., Washington, D.C.). For 
NanoSPECT/CT scanning, first, CT was performed (using a 45 KVP energy tube at 177 
mA and 180 projections with 400 ms exposure with pitch of 1), followed by helical 
SPECT of 16 projections with 60 seconds each. CT and SPECT projections were 
reconstructed using InvivoScope software (Bioscan, Inc., Washington, D.C.). The high-
resolution NanoSPECT/CT anatomical and radioactive data-sets have isotropic voxel 
size of 0.4 and 0.6 mm respectively. 
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3.2.3 MOMIA Synthesis 
 DOTA-Gly-Ser-Gly-Lys(Cypate)-E-Ahx-NH2,LS444, was synthesized and 
radiolabeled with 111InCl3 (MSD-Nordion, Kanata, ON, Canada, 3.0 microcuries (µCi)) in 
aqueous buffer (190µl, 0.4 M sodium acetate, pH 4.5, 30 min, 98 °C) as described 
previously (Zhang and Achilefu). Labeling efficiency and radiochemical purity were 
checked by HPLC (Supelcosil ABZ + PLUS, HPLC Column, 15cm X 4mm, 5µm) with a 
gradient of H2O and acetonitrile containing 0.1% TFA. The radiochemical purities of 
peptides used in the studies were always above 95%. The specific activity was 223.0 
µCi/nmol. 
3.2.4 Experimental Protocol 
 Animal handling and preparation was performed according to the guidelines 
approved by the Washington University School of Medicine Animal Studies Committee 
for humane care and use of laboratory animals. A flowchart of the acquisition timeline is 
presented in Figure 3.1A. The rats (n=5, 200-250 g Female Sprague Dawley, HSD, 
Indianapolis, IN) were first anesthetized via a mixture of ketamine and xylazine (85 
mg/kg and 15 mg/kg IP). The MOMIA imaging agent (100 µL of 111In-LS444) was 
then administered via forepaw injection. Concurrent FMT/SPECT/CT imaging was 
performed immediately after injection.  
 The DOT imaging fiber array was securely positioned on top of the rat, which was 
then advanced into the NanoSPECT/CT imaging chamber (Figure 3.1B). The 
SPECT/CT scanning regions were selected to include the injection site as well as the 
DOT imaging pad by top-view topogram. CT was performed followed by helical 
SPECT, with total acquisition times of 5 and 16 minutes respectively. To evaluate the 
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influence of the DOT array on the SPECT/CT data-sets, we also acquired SPECT/CT 
data without the DOT fiber array with the same imaging protocol as described earlier 
(Figure 3.1C).  
 For reference and verification of 111In-LS444 uptake by the lymph nodes (LNs), 
reflectance fluorescence images were acquired in vivo before and after removal of 
overlying skin following euthanasia using the near-infrared (NIR) reflectance 
fluorescence system (Pearl, LiCor Biosciences, Lincoln, NE). Lymph nodes were excised 
post-mortem and examined with the Pearl imaging system and dosimeter to further 
validate the origin of the fluorescent and the radioactivity signals respectively. In 
addition, the resected lymph nodes were frozen in OCT and sectioned in the cryostat to 
8-µm thickness. NIR fluorescence (775 +/- 55 nm excitation and 810 nm long pass 
emission filters) and brightfield microscopy images were acquired using Olympus BX51 
upright epifluorescence microscope (Olympus America, Center Valley, PA). The same 
slides were stained with hematoxylin and eosin (H&E) and imaged with fluorescence 
microscopy.  
 To evaluate the performance of the system as a function of depth, we followed the 
approach used for the stand-alone FMT system (chapter 2) (Metasebya Solomon et al.), 
but in this instance with MOMIA targets. The tissue mimicking phantoms were 
constructed by mixing agarose (Sigma-Aldrich, Saint Louis, Missouri) with intralipid 
(20% fat emulsion, Fresenius Kabi, Germany), and India ink (Speedball, Statesville, 
North Carolina) to obtain the appropriate absorption and scattering properties with µa = 
0.19 cm-1 and µ's = 3.4 cm-1. The mixture was poured into a mold and allowed to 
solidify at room temperature. Targets consisting of 3 mm diameter plastic tubes filled 
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with the MOMIA agent were prepared and embedded at 4, 7, 10 mm depths in the tissue 
simulating phantoms. The imaging protocols described above were implemented to 
acquire optical and nuclear data-sets of the phantoms with targets at different depths.  
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Figure 3. 1:  Schematic experimental setup and timeline of the multimodal experimental 
protocol. (A). Timeline of the multimodal experimental protocol. (B) Picture showing 
the placement of the fiber array on a preclinical animal model before advancing into the 
NanoSPECT/CT imaging chamber. (C) Schematic of the fiber array to demonstrate its 
effect on the transmitted x-ray beam.  
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3.2.5 Fluorescence DOT Reconstruction 
 We generated a subject-specific three-dimensional (3D) finite-element model (FEM) 
(Figure 3.2). Using anatomical data of rats obtained from 3D X-ray CT projections 
(Figure 3.2A), we created a tetrahedral mesh using MimicsTM with a maximum inter-
nodal distance of 1 mm both on the surface and within the mesh volume. The mesh, 
composed of 400,399 linear tetrahedral elements connected by 67931 nodes, was 
segmented into two tissue types: bone and soft tissues and assigned their corresponding 
optical properties (µa = 0.17 cm-1, µ's = 24 cm-1 and µa = 0.19 cm-1, µ's = 34 cm-1 
respectively) (Figures 3.1C and D). A heterogeneous tissue model was employed because 
previous studies have shown improvements relative to light models that assume 
homogeneous optical properties (Metasebya Solomon et al.; Niedre, Turner and 
Ntziachristos; Dehaes et al.; Heiskala et al.; Eggebrecht et al.). For the tissue-simulating 
phantom imaging, we also used the 3D phantom X-ray CT projections and created a 
homogeneous mesh and assigned the corresponding optical properties (µa = 0.19 cm-1, 
µs' = 34 cm-1). A second anatomical CT data-set of each rat and tissue mimicking 
phantom was obtained with DOT fibers in place and was used to obtain the 3D 
coordinates of the optodes (sources and detectors) positions (Figure 3.1B). The resulting 
FEM mesh and co-registered source and detector locations were used for light modeling 
(Figure 3.1E).  
 The light transport through the tissue was calculated using NIRFAST following our 
previously reported methods (Dehghani et al.). Briefly, an adjoint approach to 
constructing the Jacobian was used to construct a sensitivity matrix. The construction of 
the sensitivity matrix specific to fluorescence imaging follows the methods previously 
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described (see chapter 2 (Metasebya Solomon et al.)). The sensitivity matrix maps the 
relationship between the optical parameters (fluorescence distribution) and the 
measurements (Ntziachristos and Weissleder "Experimental Three-Dimensional 
Fluorescence Reconstruction of Diffuse Media by Use of a Normalized Born 
Approximation") following the normalized Born approach (Metasebya Solomon et al.). 
We directly invert the sensitivity matrix via a Moore-Penrose generalized inverse 
(Metasebya Solomon et al.; Culver, Durduran, et al.). The experimental source-detector 
measurements are converted into images by matrix multiplication with the inverted 
matrix. The recovered fluorescence yield of the tissue at each FEM node is then 
presented in 3D. The mesh nodes are then transformed to a voxellated three-
dimensional space of 1 mm isotropic voxel space for integration with SPECT/CT (the 
point spread function (PSF) of the FMT system is ~1.2 cm at 1 cm depth (Metasebya 
Solomon et al.). 
 The accuracy of the reconstructed FMT image is further improved by using the 
radioactivity measurement obtained from SPECT as a spatial priori to create a binary 
mask. The mask is then multiplied with the simulated light propagation matrix 
(sensitivity matrix) to constrain the FMT image reconstruction. 
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Figure 3.2: Fluorescence DOT Image Reconstruction. (A) An X-ray CT is used to 
capture the three-dimension structure of the anatomy of a rat. (B) X-ray CT image with 
the fiber array of DOT used to obtain optode positions. (C) Sagittal section of the 
anatomical X-ray CT image after segmentation into bone and soft-tissue region using 
MimicsTM. (D) 3D finite element model (FEM) of small animal half-body mesh 
generated from CT within MimicsTM to be used for forward modeling of light 
propagation.(E) Small animal mesh after projection of the optodes (source (red) and 
detector (blue)). Sensitivity matrix is then generated using the mesh and the 
measurement parameters as the main inputs for the FEM modeling of light in tissue 
using NIRFAST (Dartmouth). 
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3.2.5 Quantification of the Influence of FMT Fibers on 
SPECT and CT 
 We evaluated the potential for the presence of the optical fibers to negatively impact 
the imaging performance of the SPECT/CT imaging systems. The influence of the 
optical fibers on the transmitted x-ray depends on the linear attenuation coefficient (µ) 
of glass fibers at a given energy window and the thickness of the fiber arrays (l) (Figure 
3.1C). The fraction of the transmitted x-ray beam is calculated using the following 
equation, , where Io and I are the incident and the transmitted X-ray beams 
respectively and l is the effective thickness of the glass fiber elements. 
 In addition, the normalized root mean square error (NRMSE) is used to quantify 
the distortions induced in the nuclear data due to the presence of the optical fibers: 
; where X is the nuclear image with DOT fiber array and Xref 
is the reference image without the optical fibers. N is the total number of image pixels. 
NRMSE is computed for both the SPECT and X-ray CT data-sets. 
3.2.6 Quantifying Image Quality: Localization Accuracy 
 The localization accuracy of the FMT reconstruction compared to their 
corresponding SPECT data-sets was evaluated by calculating the absolute error in the 
center of masses’ (of the optical and nuclear contrasts) of the lymph node volumes. The 
mean fluorescence and radioactivity intensity values in the XYZ-planes were computed 
for each subject from the reconstructed nuclear and optical data-sets to compute the 
center of masses (COMs). In addition, the absolute error of the COMs was computed to 
0
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assess the positional error between the fluorescence and radioactive distributions. The 
COMs and COMs error of the reconstructed MOMIA tubes were also computed by 
averaging the fluorescence and radioactive intensity values for each experimental depth. 
In addition, quantitative comparison of the difference in spatial resolution was quantified 
by comparing the volumetric ratio of the ROIs between the nuclear and optical data-sets 
of the various depths of the reconstructed tubes.  
3.3 Result 
 The goal of this study was to demonstrate the feasibility of combining fiber-based 
FMT with NanoSPECT/CT. This combined nuclear-optical platform obtained data 
from both contrast mechanisms concurrently in space and time. Signal from a 
monomolecular multimodal imaging agent (MOMIA), 111In-LS444, was used to facilitate 
the spatial integration of the nuclear and optical data. 
 The potential influence of the optical fibers on the nuclear imaging data-sets was 
evaluated both by computing the X-ray beam attenuation due to glass fibers and, more 
directly, by measuring the variance introduced into the CT and SPECT signals by the 
DOT fiber array. The experimentally derived transmission losses for the X-ray beam 
were consistent with the trends of the theoretical estimates based on attenuation 
coefficients (energy dependent) of the glass fiber (Table 3.1). Model calculations estimate 
the X-ray beam transmission through the fiber array to be 31% for CT (45 keV) and 68 
% for SPECT (245 keV). 
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 SPECT  CT  
Radiation Energy (E) 245 keV (111In)  45 keV 
Attenuation coefficient of  glass, µ(E), cm-1 0.256  0.781  
Thickness (l ) in cm 1.5  1.5  
Transmission [%] 68  31  
Table 3. 1: Evaluation the effect of fluorescence DOT fiber arrays on the transmitted 
X-ray beams of the nuclear imaging system 
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Figure 3. 3: Evaluating the influence of fiber arrays on SPECT and CT images: (A) X-
ray CT image of a rat with the fiber array of DOT. (B) X-ray CT image of the same rat 
shown after removing the voxels related to the fiber array of the DOT. (C) X-ray CT 
acquired after removing the DOT imaging pad. The anatomical structures acquired 
without the fibers are used to display the fluorescence and radioactive distribution for all 
5 rats. (D) SPECT data acquired at the presence of DOT fiber array depth in a rat 
following injection of multimodal imaging agent,111In-BS255, into the left forearm. (E) 
SPECT data of the same rat acquired after removing the fibers.  
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 The computation of the NRMSE also demonstrated the existence of distortion 
introduced by the optical fibers (Figure 3.3A) in the nuclear data. The NRMSE between 
the X-ray CT anatomical data with and without FMT imaging fibers (Figure 3.3B and 
3.3C) is 8.5%. The NRMSE between the radioactive data-sets acquired in the presence 
(Figure 3.3D), and absence (Figure 3.3E) is found to be 3.1 +/- 1.3 %, which also 
accounts for the additional MOMIA accumulated in LNs during the process of acquiring 
the reference SPECT measurements. For improved visual reference, the fluorescence 
and radioactive data are co-registered and displayed on anatomical x-ray CT obtained 
after removing the DOT fiber arrays (Figure 3.3E) for the remainder of the manuscript. 
 Images of the MOMIA targets in tissue mimicking phantoms confirm the 
localization of the targets in the range of the depths from 5-10 mm (Figure 3.4, Tables 
3.2 and 3.3). The average absolute error between the COM of the optical and nuclear 
data-sets for all three depths was 4.1 +/- 2.1 mm. The average depth dependent spread 
of the volume of the FMT compared to the SPECT was 2.4 +/- 0.95 after thresholding 
at 30% maximum. 
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 Figure 3. 4: Depth sensitivity analysis with phantom studies. (A) 3D finite element 
model (FEM) mesh of the tissue phantom with the positions of the optodes (source 
(red) and detector (blue)). These were used to model light propagation. (B) Sagittal and 
Transverse Views of reconstructed experimental data from a 3mm tube target, filled with 
MOMIA contrast, whose center of mass is located at either 4, 7 or 10 mm depths. The 
fluorescence data shown is thresholded to >30% of max sensitivity. (C) Sagittal and 
transverse view of reconstructed fluorescence tube after incorporating SPECT contrast 
as a prior in the reconstruction. (D) Sagittal and transverse view of the SPECT-CT 
image demonstrate localization of the MOMIA at various depths.   
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COM {X, Y, Z} 
 in mm 
COM 
Error 
(mm) 
DOT to SPECT 
Volumetric 
Ratio 
DOT to SPECT 
Volumetric Ratio 
(>30 % maximum 
fluorescence 
intensity) 
Shallow 
DOT = {8.4, 4.6, 31.9} 
3.4 3.7/1 1.3 /1 SPECT = 
{11.7,4.7,31.5} 
Mid 
DOT = {12.6,6.7,31.9} 
6.4 4.3/1 2.9/1 SPECT = 
{10.1,7.4,37.7} 
Deep 
DOT = {12.3,7.6,41.2} 
2.5 5/1 3/1 SPECT = 
{11.2,9,39.5} 
 
Table 3. 2: Quantitative comparison of the localization between nuclear and optical data 
sets.  
 
 
 COM {X, Y, Z} in mm 
COM Error 
(mm) 
DOT to SPECT Volumetric 
Ratio 
Shallow 
DOT = {10.9, 4.1, 34.1} 
2.6 0.9/1 
SPECT = {11.7,4.7,31.5} 
Mid 
DOT = {9.6,6.3,35.1} 
2.9 0.85/1 
SPECT = {10.1,7.4,37.7} 
Deep 
DOT = {11.1,7.4,37.7} 
2.3 0.7/1 
SPECT = {11.2,9,39.5} 
 
Table 3. 3: Quantitative comparison of the localization between nuclear and optical data 
sets when SPECT is used to constrain the DOT reconstruction. 
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 The co-registered molecular information with its corresponding anatomical 
structure, Figure 3.5, demonstrates the feasibility of obtaining measurements with FMT 
and SPECT molecular contrasts and structural information with X-ray CT. An 
anatomical X-ray CT of a rat provided structural information that facilitated 
segmentation of different tissue types including bone and soft-tissue. The tissue 
segmented structure was used to generate a finite element mesh and the corresponding 
optical properties of the different tissue types were assigned to each FEM element to 
provide an accurate light propagation model for the FMT forward calculation (Figure 
3.2).  
 Reconstructed FMT images show uptake of the MOMIA by the LNs in the axillary 
region (Figure 3.5A). The localized radioactive signal in the axillary region of the 
SPECT/CT image also demonstrated the uptake of the MOMIA by the axillary LNs 
(Figure 3.5B). The high radioactive signals on the left forepaw, at the injection site, show 
the starting point of the lymph tract that leads to the axillary nodes. Due to the limited 
field of view of the FMT fiber array, the injection site is not visible in the reconstructed 
FMT image. 
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Figure 3.5: Representative Sentinel Lymph Node Mapping using Optical and Nuclear 
Imaging Systems. (A) DOT-CT image of the fluorescent LNs shown at 2mm depth in a 
rat following injection of multimodal imaging agent, 111In-LS444, into the left forearm. 
(B) SPECT-CT image demonstrating localization of axillary lymph node identified by 
accumulation of the multimodal imaging agent. 
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 The uptake of 111In-LS444 by the axillary LNs was further validated by combining 
the SPECT and FMT data-sets. The co-registered FMT/SPECT/CT images, Figure 
3.6A, demonstrate co-localization of the multimodal agent in a spatially coincident 
region. The co-localization confirms that the radioactive and fluorescent signals originate 
from the same location corresponding to the LNs. The low overlap percentage can be 
attributed to the difference in resolution (or point spread function) between the optical 
and nuclear imaging systems and the presence of fractional component of non-
radiolabeled LS444. However, the free LS444 fractional component is expected to be 
very minimal due to the high radiochemical purities of peptides used.  
 Having demonstrated the co-localization of the fluorescence and radioactive 
distribution, we explored a simple method to incorporate the high resolution 
NanoSPECT/CT radioactive data into the DOT image reconstruction to improve the 
localization accuracy of the axillary LNs signal. A binary mask, created from the 
radioactivity distribution of the SPECT data was multiplied with the simulated light 
propagation matrix to constrain the FMT image reconstruction. The SPECT/CT 
measurements fused with the FMT data-sets reconstructed with a priori, Figure 3.6B, 
demonstrated an improvement in congruency of the radioactive and fluorescence signal 
in the axillary regions. As a result of using SPECT as a hard prior, the overlap between 
DOT and SPECT is inherently unity. Likewise, it is assumed that the fluorescent signal 
originates from conjugated complexes and not from free optically active fragments. A 
soft prior approach to relax these conditions is suggested below. The average spatial 
discrepancy between the COM of the optical and nuclear data-sets for all five rats was 
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2.68 +/- 1.0 mm and 1.33 +/- 0.85 mm before and after incorporating SPECT as a 
priori respectively. 
 
 
Figure 3. 6:Multimodal Sentinel Lymph Node Imaging. (A) Co-registered FMT-
SPECT-CT image demonstrate co-localization of the MOMIA in spatially coincident 
region in 5 rats. (B) Demonstrate robust co-localization on the co-registered FMT-
SPECT-CT image after using SPECT as a prior. 
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 Reflectance fluorescence images were captured using the Pearl NIR fluorescence 
imaging system before sacrificing the animal to confirm the nuclear and DOT results. 
Reflectance fluorescence images acquired after euthanasia and removal of overlying skin 
further confirmed MOMIA uptake by the lymph nodes localized by DOT and SPECT 
(Figure 3.7A). The uptake of the MOMIA by axillary lymph nodes (inset on Figure 3.7A) 
was further confirmed with combined fluorescence and bright field microscopy (Figure 
3.7B). In addition, the H&E stains validate the excised organ as lymph nodes due to the 
presence of centroblasts (dark zone) and centrocytes (light zone). 
 
Figure 3.7: (A) Representative planar reflectance image of the sentinel lymph node 
regions demonstrating fluorescence from the injection site (paws) and the lymph vessels 
leading to the axillary lymph nodes (arrow) of the rats after euthanasia and removal of 
the skin. In set fluorescence from ex vivo imaging shows MOMIA uptake in the lymph 
nodes. (B) Representative microscopy images of fluorescent sentinel lymph nodes. 
Montages are a composite of brightfield and fluorescence microscope at top left and 
brightfield at top right. The bottom left and right represent fluorescence and H&E 
stained section respectively.  
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The radioactivity measured from excised LNs with a dosimeter demonstrate an 
uptake of approximately 0.45+/-0.17 % µCi (n=4) of the injected dose per SLN. The 
tracer uptake of sentinel nodes is highly variable as the lymph flow depends on factors 
such as massaging the injection site. For instance, in a study of melanoma cancer 
patients, uptake in the SLNs ranged from 0.00139-6.8% of the injected tracer dosage 
(Kapteijn et al.). 
3.4 Discussion 
The multimodal optical-nuclear platform shown has the potential to elucidate 
underlying biological mechanisms relevant to a wide array of diseases. We established the 
feasibility of integrating a fiber-based, video-rate FMT system with a preclinical 
NanoSPECT/CT platform. We used our recently developed MOMIA, which has the 
unique structural feature that both signals (fluorescence and radioactivity) emanate from 
the same source. The NIR fluorescent molecular probe, LS444, served as a contrast 
agent for FMT, while the 111ln served as a source of signal for SPECT imaging to 
facilitate the fusion of the optical and nuclear data-sets with high spatial precision. 
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 In this chapter, we evaluated the FMT/SPECT/CT system for imaging LNs in rats. 
CT provided high-resolution, co-registered anatomy. The combined optical-nuclear 
imaging demonstrated co-localization of a MOMIA in a spatially coincident region. We 
further demonstrated the congruency of the co-localization by incorporating SPECT as a 
prior in the DOT reconstruction. The average spatial discrepancy in the COMs of the 
contrasts between SPECT and FMT improved from 2.68 +/- 1.0 mm to 1.33 +/- 0.85 
mm after incorporating SPECT into the FMT reconstruction. 
 Data-sets acquired separately with optical and nuclear platforms have been 
integrated previously (Kapteijn et al.; Nahrendorf et al.). For instance, Nahrendurfet et. 
al. demonstrated the similarity between FMT and PET by combining the two data-sets 
acquired sequentially on two different scanners using fiducial markers to co-register the 
data (C. Q. Li et al.). A strength of the current simultaneous optical-nuclear system is 
that it avoids potential misalignment of data-sets due to involuntary non-uniform 
movement of tissues during repositioning. Furthermore, the datasets in the presented 
study are co-registered in time. The first small animal study where optical imaging (scan 
rate not reported) was physically integrated into a PET system was reported by Li et al. 
(Nahrendorf et al.). Localization of the tumor with simultaneously acquired nuclear and 
optical datasets was performed after injection of two separate contrast agents (for 
fluorescent and radioactive detections) at different time points, separated by 24 hours, 
thus the data-sets were not co-registered in time. Further, acquisition of the anatomical 
information using a different scanner might lead to co-registration error of the functional 
molecular data with reference anatomy. To a significant extent, the system presented in 
this paper addresses many of these difficulties by combining three modalities 
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(FMT/SPECT/CT) within a single device. The FMT/SPECT/CT platform acquires the 
different functional (fluorescent and radioactive) and anatomical data either 
simultaneously or sequentially without moving the subject from the bed. This design 
essentially eliminates differences in subject positioning and minimizes misalignment due 
to involuntary internal organ motion.  
 While the current study does not focus on the dynamics of the lymph node 
accumulation, we have previously reported the capability of the FMT system for 
dynamic imaging by monitoring and generating time-course data of the lymphatic 
dynamics for indocyanine green (ICG) (Metasebya Solomon et al.). Accumulated dye in 
the axillary region of rats was imaged to a depth of 10-12 mm over a 10-minute time-
course.  Future studies will be needed to explore dynamic imaging of pharmacokinetics 
and pharmacodynamics for multimodal contrast agents.  
 Optical imaging can leverage the SPECT and CT information to improve accuracy 
during data processing and image reconstruction (Cao and Peter; A. Li et al.). For 
instance, we generated a small animal 3D finite-element model (FEM) using the 3D 
anatomical projections obtained from an X-ray CT to improve forward modeling of light 
propagation. In addition, incorporating SPECT data into the FMT reconstruction 
augmented the localization accuracy. An important future area of work is in developing 
algorithms to incorporate the SPECT data as a soft-prior in the FMT reconstruction to 
optimize the fusion of the two data types (Cao and Peter). 
 The current FMT system setup has high dynamic range and linear response and 
accurate localization at various depths as shown with phantom studies. However, several 
potential improvements of the fiber-based, video-rate FMT system can still be identified. 
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For instance, the sensitivity of the optical imaging in general is expected to decline with 
imaging depth, while SPECT has no depth limitation and easily extends to whole-body 
imaging. Possible extensions on the current design include extending the FMT field of 
view for more complete coverage. The DOT imaging array shape and size can be 
designed based on application. For example, the imaging array could have a cylindrical 
shape with extended sources and detectors for whole-body imaging. The potential for an 
expanded fiber array system with up to 48 sources and 48 detectors has been 
demonstrated for brain imaging in humans (White et al.). A higher-density imaging array 
could also potentially increase the resolution, particularly at the shallower depths for 
accurate localization of the target (Culver, Ntziachristos, et al.). A second limitation is 
the existence of distortion/artifacts on the x-ray CT images due to the high attenuation 
coefficient of borosilicate glass fibers compared to the bone. The possibility of whether 
switching to optical fibers composed of materials with lower attenuation than bone 
would reduce the artifacts remains a question for future investigation.  
 Another area of future work is to leverage the complementary contrast mechanisms 
of SPECT/FMT to evaluate biological mechanisms. MOMIAs that use activatable 
optical contrast mechanisms provide complementary information to the "always-on" 
SPECT information. SPECT can be used for whole-body imaging to localize the 
diseased tissue based on maps of the concentration of molecular targeted imaging agents 
while the FMT would report local molecular events, such as enzymatic activity, to 
monitor therapeutic response (H. Lee et al.). 
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3.5 Conclusion 
 We demonstrated integration of a fiber-based, video-rate fluorescence mediated 
tomography system with a preclinical NanoSPECT/CT platform. The video-rate FMT 
can accommodate the various imaging bore sizes of nuclear imaging systems due to the 
flexibility of the imaging fiber array. We used a monomolecular multimodal imaging 
agent such that the nuclear and optical signals emanated from the same regions to 
facilitate the fusion of both data-sets with high spatial precision. The depth profiling 
capability of the FMT was confirmed in phantoms by localizing MOMIA targets in 
tissue mimicking phantoms in the range of depths from 5-10 mm. The average absolute 
error between the COM of the optical and nuclear datasets for all three depths was 4.1 
+/- 2.1 mm and the depth dependent spread of the volume of the FMT compared to 
the SPECT was 2.4 +/- 0.95 after thresholding at 30% maximum. For in vivo imaging, 
we used the anatomical X-ray CT data-sets to generate 3D finite-element model for light 
propagation. Co-localization of the MOMIA in both the FMT and SPECT contrasts was 
demonstrated. We also observed improvement in spatial correlation of the co-registered 
datasets after incorporating SPECT as a priori to constrain the FMT data reconstruction. 
The average spatial discrepancy of the LNs COMs between FMT and SPECT improved 
from 2.68 +/- 1.0 mm to 1.33 +/- 0.85 mm after incorporating the SPECT as a prior 
into the FMT reconstructions. These results suggest that integrated multimodal 
FMT/SPECT/CT has the potential to become a powerful and practical tool for a broad 
array of real time imaging applications. 
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Chapter 4 
 
FMT/CT Guided Dynamic Imaging of 
Optical Tracers for Small Animal 
Imaging  
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4.1  Introduction 
 Dynamic fluorescence imaging is an emerging technology that can provide 
enhanced non-invasive functional and molecular level details and is a promising tool for 
detection of abnormal anatomical or physiological conditions based on kinetic 
parameters related to perfusion, pharmacokinetics, and tissue metabolism.  
 Currently, dynamic fluorescence imaging has been applied to studies of 
biodistribution of various optical agents in basic biological research (Achilefu and 
Dorshow; Amoozegar et al.; El-Desoky et al.; Goiffon et al.; Hillman et al.; Hillman and 
Moore; Patwardhan and Culver; Welsher, Sherlock and Dai). While dynamic imaging via 
fluorescence reflectance imaging (FRI) recently allowed segmentation of various internal 
organs based on their different kinetic behaviors(Hillman and Moore; Welsher, Sherlock 
and Dai), FRI sensitivity declines quickly with depth and a 2D geometry precludes co-
registration with 3D modalities such as MRI, CT, PET or SPECT. Three-dimensional 
fluorescence mediated tomography (FMT) provides improved deep tissue sensitivity, 
volumetric localization and increased quantitative accuracy. FMT systems typically image 
on time scales of minutes to hours, which is too slow to monitor the uptake dynamics of 
a vascular injection.  
 In this work, we overcome this limitation and demonstrate dynamic tomography of 
fluorescent diagnostic imaging agents in healthy mice and in mice with liver disease. We 
demonstrate that video-rate FMT is fast enough to enable imaging of cardiac, respiratory 
and pharmacokinetic induced dynamic fluorescent signals and that the real-time uptake 
of injected agents can be deduced from these measurements. Fiber-based, video-rate 
FMT can additionally improve the flexibility of imaging by adapting to varying tissue 
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curvatures and performing simultaneous multiple point illumination and collection, thus 
increasing the imaging frame rate. In addition, for improved delineation of target tissues, 
we have combined FMT with CT to obtain complementary information. X-ray CT 
provides anatomical information while FMT provides dynamic functional information. 
Anatomically guided dynamic fluorescence mediated tomography was made possible by 
combining our recently published fiber-based, video-rate FMT system (Metasebya 
Solomon et al.) with preclinical NanoSPECT/CT (Bioscan).  
 Dynamic fluorescence mediated tomography (DyFMT) used in conjunction with 
tracer kinetic modeling promises to be an effective tool for non-invasive quantification 
of molecular imaging analysis (Liu et al.; Milstein, Webb and Bouman). Tracer kinetic 
modeling allows extraction of clinically or experimentally relevant information related to 
physiological and molecular processes. Kinetic models require two main measurements 
of tracer concentration over time as inputs (van den Hoff; Willemsen and van den Hoff). 
The two key measurements are tracer time course in arterial blood, used as a forcing 
function, and the corresponding tracer time course in the organ of interest, the 
“response.” 
 Some challenges exist that limit the application of compartment modeling on a 
routine basis or for longitudinal studies relating to small animal imaging (Laforest et al.; 
van den Hoff; Willemsen and van den Hoff). The gold standard for obtaining an input 
function is through manual acquisition of arterial blood samples, a technique that yields a 
limited temporal resolution (Laforest et al.). In addition, frequent arterial blood sampling 
is an invasive technique that has multiple drawbacks. First, the number of arterial blood 
samples collected is limited because it is inconvenient and hard to access the small blood 
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vessels of small animals. Second, the amount of blood volume withdrawn is limited to a 
small fraction of the total blood volume of the animal to avoid blood depletion and keep 
the animal alive. Furthermore, the loss of blood may perturb the animal physiology and 
induce a bias in the experimental outcome. It may also limit or prevent repeated 
assessment of the same animal for longitudinal studies. Non-invasive techniques such as 
factor analysis methods and region-of-interest based (image-derived) input functions are 
proposed to resolve some of the challenges associated with serial arterial blood sampling 
for routine implementation of kinetic modeling in small animal studies (Laforest et al.; 
van den Hoff; van der Weerdt et al.; Willemsen and van den Hoff; Wu, Hoh, et al.; Wu, 
Huang, et al.; Hoekstra, Hoekstra and Lammertsma).  
 In this work, we propose to implement our application using a plasma input 
function, derived from dynamic FMT images. This approach is noninvasive in nature 
and helps simplify the scanning protocol. We demonstrate, for the first time, the 
feasibility of implementing time traces extracted from highly vascularized region-of-
interest, the heart region, as image-derived input function (IDIF) for dynamic 
fluorescence tomography. The IDIF was validated against the reference input functions, 
arterial blood samples, to fulfill the requirement of compartmental modeling and kinetic 
parameter estimation for fluorescence dynamic imaging studies. The second input to the 
compartmental modeling, time resolved signal curves of target regions, was obtained 
from the fluorescence dynamic imaging series guided by organ locations shown in the 
corresponding X-ray CT data. Furthermore, feasibility studies were performed to 
distinguish healthy and diseased target regions uptake and clearance rates by 
implementing a two-compartment model. In summary, this technique provides a 
    
 
89 
powerful pharmacokinetic analysis of optical agents, with the potential for detecting the 
disease state of the internal organs and monitoring their response to therapeutic agents.  
4.2 Materials and Method 
4.2.1 Fiber-based, video-rate FMT System 
 For this study, we used our previously published fiber-based, video-rate 
fluorescence mediated tomography system, which consists of a grid of alternating 12 
sources and 13 detectors (Metasebya Solomon et al.) Each source position is composed 
of two near infrared laser diodes (785 nm, Thorlabs DL7140-201S, and 830 nm, 
Thorlabs HL8325G) with dedicated drivers and control lines for each source to allow 
flexible software configurable source encoding (frequency- and time- encoding). Light 
sources are coupled into 2.5 mm diameter fiber bundles made of borasilicate glass 
sheathes with lightweight silicone. The detection channels use optically-filtered discrete 
avalanche photodiodes (Hamamatsu C5460-01) digitized with dedicated 24-bit analog-
to-digital converters (MOTU HD 192). The custom made narrowband optical filters 
(CVI) have an 830 +/- 10 nm center wavelength and an out-of-band rejection of OD4, 
thus blocking the excitation light while passing the fluorescent and reference signals. An 
aspheric lens is used to collimate the light and optimize the blocking of the excitation 
light by the narrowband interference filter in order to enhance fluorescent signal 
detection. With this scheme, we acquire frequency-encoded fluorescence emission and 
reference transmission (used to normalize the measured fluorescence) light levels 
concurrently at each detector. This ratio-metric data allows DOT reconstructions using 
the normalized Born approximation, resulting in a map of quantified fluorochrome 
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distribution (Ntziachristos and Weissleder "Experimental Three-Dimensional 
Fluorescence Reconstruction of Diffuse Media by Use of a Normalized Born 
Approximation"). All data are acquired at frame rate of 30 Hz. A total of 88 
measurements from source-detector pairs representing the first (6 mm) and second (13 
mm) source-detector pairs are used for image reconstruction. The DOT imaging array 
composed of 3 cm wide by 3 cm high flexible silicone with right-angle fibers is 
integrated with the NanoSPECT/CT system.  
 The ratio-metric data of light intensities of transmission and fluorescent acquired 
concurrently at each detector is discretized according to the normalized Born approach 
to obtain y=Ax, which is followed by direct inversion using a Moore-Penrose 
generalized method to obtain fluorescence image reconstruction (Culver, Siegel, et al.; 
Ntziachristos and Weissleder "Experimental Three-Dimensional Fluorescence 
Reconstruction of Diffuse Media by Use of a Normalized Born Approximation"; 
Patwardhan and Culver; M. Solomon, B. R. White, et al.; Zeff et al.). Optical properties 
at the reference wavelength of µa = 0.1 cm
−1 and µ's = 10 cm
−1 were used to model the 
optical properties of the mouse for in vivo studies (Cheong, Prahl and Welch). Further 
reconstruction and design details as well as capabilities of the fiber-based, video-rate 
FMT are detailed in a previous publication (Metasebya Solomon et al.). 
4.2.2 CT Acquisition 
 For improved delineation of tissue/target volumes, we have combined FMT with 
microCT to obtain complementary information. X-ray CT provides anatomical 
information while FMT provides dynamic functional information. Our fiber-based, 
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video-rate FMT system was inserted into NanoSPECT/CT platform (Bioscan, Inc. 
Washington, D.C.) for co-registration of fluorescence and nuclear imaging data sets. The 
rat bed and 9-pinhole collimator sets were used to accommodate mouse and DOT 
imaging fiber array as previously described (chapter 3). The whole body CT scanning 
regions, including the DOT imaging pad, were selected by top-view topogram and the 
total acquisition time was 5 minutes. CT scanning was performed using a 45 KVP energy 
tube at 177 mA and 180 projections with 400 msec exposures with pitch of 1. CT 
projections were reconstructed using InvivoScope software (Bioscan, Inc. Washington, 
D.C.). The high-resolution NanoSPECT/CT anatomical data sets have isotropic voxel 
size of 0.4 mm. 
4.2.3 Experimental Protocol 
 Animal handling and preparation was performed according to the guidelines 
approved by the Washington University School of Medicine Animal Studies Committee 
for humane care and use of laboratory animals. A flowchart of the acquisition timeline is 
presented in Figure 4.1. Mice (n= 5 healthy and n=6 mice with liver disease) were 
anesthetized with an intraperitoneal injection of ketamine (85 mg/kg) and xylazine (15 
mg/kg) cocktail.   
 The dynamic fluorescence intensity was monitored for 10 minutes following tail 
vein bolus injection of 80 𝜇M of ICG (Indocyanine green, Sigma-Aldrich, St Louis, MO) 
via a catheter secured in the tail vein. The DOT imaging fiber array was securely 
positioned on the ventral side of each mouse to image the heart, lung and liver regions 
(Figure 4.1B). We continuously acquired images at the rate of 30 frames per second (fps) 
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to capture the initial rapid change in signal levels associated with the uptake and washout 
of the optical tracer in the blood and different tissues, with maximum time resolution. 
Arterial blood samples were collected before and during the optical data acquisition 
period using micropipette tubes by capillary action. Initially, continuous blood sampling 
from the tail artery is achieved every 15 seconds for the first two minutes in order to 
capture the fast dynamics of the first few minutes of the contrast agent time course. The 
continuous sampling was performed every 1-minute until the end of the imaging session 
to minimize the effect of blood loss on the animal physiology. The micropipette tubes 
are then imaged using the Pearl near-infrared (NIR) fluorescence imaging system (LiCor 
Biosciences, Lincoln, NE).   
 To induce liver apoptosis, FasL (Jo2 clone, BD Pharmingen) was administered 
intraperitoneally into the mice (n=6) (0.15 ug/g) 4 hours before imaging (Ogasawara et 
al.; Janin et al.). FasL is a monoclonal antibody that targets ligand Fas receptors (also 
known as “Death” receptors) and activates apoptotic responses of hepatocytes and 
endothelial cells that express the Fas receptors (Ogasawara et al.; Janin et al.; Goetz et 
al.). At the end of the dynamic fluorescence data acquisition period, we also acquired 
anatomical X-ray CT data with and without the DOT fiber array using imaging protocol 
as described earlier without moving the animal.  
 For reference and verification of ex vivo ICG uptake by different organs, superficial 
fluorescence images of the excised organs were acquired at the end of imaging 
experiments after humane euthanasia using the Pearl near-infrared (NIR) reflectance 
fluorescence system. Healthy and diseased livers were isolated and fixed in 10 % 
formalin for hematoxylin and eosin (H&E) staining and histological analysis.   
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4.2.4 Segmentation 
 Using anatomical data of the mouse obtained from 3D X-ray CT projections 
(Figure 4.1C), we created a binary mask for each target regions (heart, lung and liver). 
The XYZ-coordinates of the mask are manually selected from the corresponding 
anatomical locations. A second anatomical X-ray image of mouse obtained with DOT 
fibers is used to obtain source-detector positions (Figure 4.1B). An affine transformation 
is performed to transform the masks XYZ-coordinates into a DOT space for 
multiplication with the reconstructed fluorescence dynamic data to extract its 
corresponding time courses by averaging the voxels fluorescence intensity. The accurate 
segmentation of the different functional regions is key since the average voxel time trace 
is dependent on it. Any change of the time trace, for example delay in time, might lead to 
an error in kinetic parameters estimation. To address this issue, we selected the masks 
coordinates well within the target regions.  
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Figure 4.1: Dynamic Fluorescence and Anatomical Data Acquisition Protocol. (A) 
Schematic showing the placement of the fiber array on ventral side of a mouse to 
demonstrate the source-detector arrangement and the imaging field-of-view. (B) X-ray 
CT image with the fiber array of DOT used to obtain source-detector positions for 
anatomical co-registration of the dynamic FMT data. (C) An X-ray CT is used to capture 
the three-dimension structure of the anatomy of a mouse for segmentation of target 
regions. (D) Timeline of the fluorescence and anatomical data acquisition protocol. 
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4.2.5 Compartment Modeling 
 First, the feasibility of implementing a region-of-interest based forcing function was 
validated against the reference arterial blood samples. Serial arterial blood samples were 
collected as the gold standard for pharmacokinetic analysis for validation of dynamic 
fluorescence imaging. Image-derived input functions (IDIF) were constructed from 
heart region time traces. Temporal correlations were determined using Pearson 
correlation of the heart region time traces with corresponding reference arterial blood 
samples, thus producing correlation r-value for each mouse. Second, the IDIF was used 
as input for a two-compartment model to estimate and assess ICG pharmacokinetics in 
healthy mice and mice with liver disease extracted time traces from lung and liver 
regions. To assess the in vivo pharmacokinetics of ICG in the liver and lung with and 
without drug treatment, a widely used two-compartment trapping model with three 
parameters was employed (Figure 4.2)(Willemsen and van den Hoff; van den Hoff).  
 The ''vasculature" compartment represents the kinetics of ICG remaining in 
systemic circulation. The clearance of ICG from the systemic circulation is attributed to 
its trapping and excretion exclusively into the bile through the liver without undergoing 
any biotransformation. In this model, the ''tissue" compartment is split into two-
compartments – EES and Internalized. We postulate that free ICG in the blood can 
reversibly extravasate into the tissue while no extravasation from albumin bound ICG to 
tissue is expected except in the liver (Berezin, Guo, Akers, et al.). Therefore, the 
"Extracellular Extravascular Space" compartment represents the time-resolved reversible 
extravasation of ICG in different organs of interest (lung and liver). The forward and 
reverse rate-constants of ICG between the blood and tissue are denoted by k1 (sec
-1) and 
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k2 (sec
-1), respectively. The ''Internalized" compartment represents the concentration of 
ICG that remained trapped in the tissue during the data acquisition period. The tracer is 
trapped into the tissue at a rate constant of k3 (sec
-1).  
 The tissue compartment, CT, is represented as the solution to a linear differential 
equation (Eq 1) derived assuming that rates of transport are given by a rate constant 
multiplied by the concentration of the different compartments of our model (Berezin, 
Guo, Akers, et al.; Willemsen and van den Hoff; van den Hoff). The solution of the 
differential equation is convolved with the image-derived forcing function, Cbl (Eq2) 
(Willemsen and van den Hoff; van den Hoff). Next, the output of the convolution is 
used as an input and the Nelder-Mead Simplex algorithm is used to optimize the kinetic 
parameters k1 through k3 against the target regions dynamic FMT data.  This is 
implemented through the fminsearch function in Matlab (MatLab 7.14, The MathWorks, 
Inc. Natick, MA). The overall uptake rate constant of ICG (K) (Eq 3) in the liver and 
lung is computed to compare their difference in overall ICG uptake rate (Willemsen and 
van den Hoff; van den Hoff). The accuracy of the fitted ICG curves were compared and 
validated against their matching dynamic FMT data using Pearson correlation.  
 𝑑𝐶!𝑑𝑡 = 𝑘! ∗ 𝐶!" 𝑡 − 𝑘! + 𝑘! ∗ 𝐶! 𝑡                                           1  𝐶! = 𝐶!" 𝑡   ⊗    𝑘!𝑘! + 𝑘! 𝑘! + 𝑘! ∗ 𝑒 ! !!!!! !       2 K =    𝑘!×𝑘!𝑘! + 𝑘!                                                                                                                                         3 
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Figure 4.2: Two-compartment model implemented to estimate ICG kinetic rate 
constants (k1, k2 and k3 (sec-1)) of the lung and liver tissues in healthy mice and mice 
with liver disease. 
4.3 Results 
 The goal of this study was to demonstrate the feasibility of implementing video-rate, 
fiber-based FMT-CT as a fast and non-invasive tool to obtain IDIF and assess organ 
function based on the quantitative output of kinetic modeling. The different processing 
steps involved in obtaining image-derived input functions and kinetic modeling steps to 
estimate rate constants of regions-of-interest are outlined in Figure 4.3.  
 Fluorescence concentrations over time were obtained from the dynamic imaging 
series for target regions (heart, lung and liver) guided by their corresponding anatomical 
x-ray CT data (Figure 4.4 and Figure 4.5). Figure 4.4 illustrates typical subject-specific 
masks definition of regions-of-interest manually generated from anatomical X-ray CT 
projections. The masks are used to constrain reconstructed FMT data and obtain ICG 
dynamics for anatomically defined regions.   
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Figure 4.3: Flow chart demonstrating steps towards quantitative fluorescence mediated 
tomography (FMT). IDIF= Image-Derived Input Function, ABS= Arterial Blood 
Samples. 
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Figure 4.4: Illustration of typical masks definition of target regions generated from 
anatomical X-ray CT data. (A) Representative coronal view of heart, lung, and liver (left 
to right) regions masks combined with the corresponding X-ray CT data. (B) 
Representative sagittal view to demonstrate the depth profile of the combined target 
regions masks and the profile of the DOT sensitivity matrix (blue). The target regions 
are within the DOT sensitivity. (C) Three-dimensional representation of the heart, lung 
and liver masks co-registered with its anatomical X-ray CT data. The far right image is 
the combined heart, lung and liver masks co-registered with its corresponding X-ray CT 
data. The masks are used to extract their corresponding ICG time courses to estimate 
the kinetic rate constants of each region of interest.  
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 The DOT images of ICG dynamics of heart, lung and liver regions were co-
registered with its corresponding anatomical X-ray CT projections for healthy and anti-
Fas-treated groups (Figure 4.5). Representative sagittal and coronal views of the target 
regions masks are shown in Figures 4.5A and 4.5C. Coronal slices that best display the 
dynamic fluorescence data from the heart, lung and liver are shown in Figure 4.5B and 
4.5D. Representative time traces extracted from target organs corresponding to their 
anatomical locations demonstrated distinct ICG dynamics due to their different ICG 
pharmacokinetics (in healthy mouse (Figure 4.5E) and averaged over all five healthy 
mice and all six mice with liver disease (Figure 4.5F)). Each organ demonstrated distinct 
ICG dynamics due to their different ICG pharmacokinetics. The time traces 
demonstrated ICG accumulation in the liver, which is associated with ICG uptake by 
hepatocytes	  prior to elimination in the bile. In contrast fluorescence signal from heart 
and lung regions rapidly decreased during the same time period, corresponding to ICG 
clearance from the blood. 
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Figure 4.5: Imaging of ICG Dynamics in Mice. (A & C) Sagittal and coronal views of 
the combined heart-liver masks (left to right). The blue lines of the sagittal views indicate 
the position of the coronal slice used to display the dynamic FMT-CT data. (B & D) 
Coronal view of the reconstructed fluorescence dynamic tomography, after 
segmentation, and co-registered with its corresponding anatomical X-ray CT following 
bolus injection of ICG into the tail vein of a healthy mouse.  (E) Average time courses 
of pixels extracted from the heart, lung and liver regions of a representative healthy 
mouse shown above. Each organ demonstrates distinct ICG dynamics due to their 
different ICG pharmacokinetics. (F) The dynamics of ICG of heart, lung and liver 
regions averaged over 5 healthy mice and over 6 mice with experimentally induced liver 
apoptosis (left to right). The time traces demonstrate ICG accumulation in the liver 
while the signal decreases over time in the heart and lung regions, which is associated 
with ICG clearance. In addition, the time traces of mice with liver disease show high 
standard deviation, which can be associated with the subject specific response to the 
FasL treatment that can indirectly induce high variation on ICG pharmacokinetics.  
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 The feasibility of implementing time traces derived from the heart, as forcing 
function for a two compartment model was validated against the gold standard method, 
arterial blood samples. Time traces of ICG in collected serial arterial blood samples 
shows similar dynamics to its corresponding time traces derived from the heart region 
(in a representative mouse Figure 4.6A and averaged over all fiver healthy mice and six 
mice with liver disease Figure 4.6B and 4.6C respectively). Time traces of the IDIF are 
highly correlated temporally with their corresponding arterial blood samples with a mean 
Pearson correlation coefficient of 0.95 ± 0.024 and 0.86 ± 0.083 in healthy mice  (Table 
4.1) and in mice with liver disease (Table 4.2) respectively. The high correlations 
demonstrate that the time courses from the heart region can be used as an image-derived 
forcing function for a two-compartment model to estimate ICG kinetic parameters of 
the target regions, the lung and liver.  
 
Figure 4.6: Validation of Image-Derived Input Function (IDIF) with Interpolated Serial 
Arterial Blood Samples. (A) Time traces of ICG in collected serial arterial blood samples 
compared to its corresponding time courses from heart region of a representative 
healthy mouse. (B & C) Mean time courses of ICG dynamics in systemic circulation and 
time courses extracted from heart regions and averaged of 5 healthy mice and 6 mice 
with liver disease. The heart region are highly correlated with the arterial blood samples 
with Pearson correlation coefficient of r=0.95 +/- 0.024 and 0.86 +/- 0.083 in healthy 
mice and mice with liver disease respectively.  
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 Moreover, we demonstrated the feasibility of evaluating organs function by 
comparing ICG kinetic parameters in regions-of-interest in mice with induced hepatic 
apoptosis and healthy mice. Target regions (lung and liver) measurements and their 
corresponding IDIF were used as inputs for the proposed two-compartment model. The 
estimated ICG kinetic rate constants of liver and lung regions demonstrate the feasibility 
of distinguishing different organs as well as healthy vs. diseased organs. Using the two-
compartment model, each fitted ICG concentration curve shows high temporal 
correlation with the corresponding lung and liver ICG time courses data (r= 0.95 ± 
0.059 and 0.95 ± 0.028 for lung and liver regions respectively) in healthy mice (Figures 
4.7A and 4.7B and Table 4.1). There is also high correlation between each fitted ICG 
concentration curve and the corresponding lung and liver time courses data (r= 0.92 ± 
0.047 and 0.92 ± 0.042 for lung and liver data respectively) in mice with liver apoptosis 
(see Figures 4.7C and 4.7D and Table 4.2).  
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Figure 4.7: (A & C) Examples of lung and liver regions fitted ICG time courses using 
the two-compartment model and their corresponding time courses obtained from a 
healthy mouse and mouse with experimentally induced liver disease respectively. (B & 
D) Mean dynamics of lung and liver regions ICG time courses and their corresponding 
fitted ICG time traces using the proposed two-compartment model averaged over 5 
healthy mice and 6 mice with liver disease respectively. Each fitted ICG concentration 
curve shows high correlation with the corresponding lung ICG time courses data with 
mean Pearson correlation coefficient of, r, 0.95 +/- 0.059 and 0.92 +/- 0.047 for healthy 
mice and mice with liver disease respectively. Each fitted liver ICG concentration curve 
is highly correlated with the corresponding liver ICG time courses data with mean 
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Pearson correlation coefficient of, r, 0.95 +/- 0.028 and 0.92+/- 0.042 for healthy mice 
and mice with liver disease respectively. 
 
 The average overall uptake rates of liver and lung in healthy mice were 7.4x10-4 +/- 
5.6x10-4 sec-1 and 4.48 x10-6 +/- 1.92x10-6 sec-1 respectively, which confirms that ICG is 
trapped hundredfold time more in the liver (Figure 4.8A) and that lung lower 
permeability and retention rate of ICG. The liver damage alter the kinetics of ICG 
compared to healthy mice as displayed by the increase in the overall rate constant of lung 
and liver in diseased mice as shown in Figure 4.8B. For example, the observed delay in 
excretion rate of ICG from the systemic circulation in mice with hepatic apoptosis was 
caused by the sluggish ICG uptake rate of diseased liver (Table 4.3). The mean ICG 
uptake rate (k1) of liver in mice with liver disease was decreased from 0.02 ± 0.022 sec
-1  
to 0.013 ± 0.0094 sec-1. The mean reverse rate (k2) was also diminished in mice with liver 
apoptosis to 0.074 ± 0.66 sec-1 from 0.12 ± 0.11 sec-1. The ICG internalization by 
hepatocytes was elevated from 0.0055 ± 0.0024 sec-1 in healthy mice to 0.0092 ± 0.012 
sec-1 in mice with liver disease. ICG is mainly cleared through the liver into the bile 
without undergoing any modification.  
 In addition, there was also an observed increase in the uptake and clearance rate of 
ICG in lung of mice with liver disease compared to healthy mice (Table 4.3). For 
instance, we observed an increase in lung mean uptake rate of (k1) in mice with liver 
disease from 6.8x10-4 ± 3.7x 10-4 sec-1 to 0.0161 ± 0.0094 sec-1. The mean reverse rate 
(k2) had also increased from 0.29 ± 0.21 sec
-1 to 0.48 ± 0.39 sec-1 in mice with liver 
disease. The ICG retention rate in lung cells was elevated from 0.0019 ± 0.0011 sec-1 to 
0.0031 ± 0.0036 sec-1 in mice with liver disease. Moreover, the average overall ICG 
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uptake rate of liver and lung increased from 7.4x10-4 to 1.48x10-3 sec-1 and 4.46x10-6 to 
1.03x10-3 sec-1, respectively. The observed increase in overall ICG rate constant of lung 
and liver (Figure 4.8B) is associated with leaky vasculature and cell membranes due to 
the experimentally induced endothelial cell apoptosis and vascular lesions after FasL 
administration (Ogasawara et al.; Janin et al.).  
 
Figure 4. 8: Overall ICG uptake rate constant of lung and liver regions. (A) Comparison 
of the overall uptake rates of liver and lung regions in healthy mice. The mean overall 
uptake rates of liver and lung are 7.4x10-4 +/- 5.6x10-4 sec-1 and 4.48 x10-6 +/- 1.92x10-6 
sec-1 respectively, which confirms that ICG is trapped hundredfold time more in the liver 
(Figure 8A) and that lung lower permeability and retention rate of ICG. (B) Comparison 
of the overall uptake rates of liver and lung regions in healthy mice with anti-Fas treated 
group of mice.	  The average overall ICG uptake rate of liver and lung increased from 
7.4x10-4 to 1.48x10-3 sec-1 and 4.46x10-6 to 1.03x10-3 sec-1, respectively 
 
 The change in kinetic parameters is associated with the induced morphological 
changes of hepatocytes (cell bodies and the nucleus) and endothelial cells that express 
Fas receptors (Ogasawara et al.; Janin et al.). Liver section histology verified 
morphological changes of the cell bodies and nucleus as a result of the induced 
apoptosis 4 hours after administering FasL compared to healthy liver (Figure 4.9). The 
extent and severity of the liver apoptosis after the FasL treatment is subject specific as 
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shown in Figure 4.9B. This could be the cause of the high variation (standard deviation) 
observed in the ICG time courses of mice with liver disease.  
 
 
Figure 4.9: Histological analysis of liver sections of healthy mice and mice with 
experimentally induced liver apoptosis. (A & B) Examples of hematoxylin and easin 
(H&E) stained healthy and diseased liver sections respectively.  The H&E stained liver 
sections demonstrate morphological changes of the cell bodies and the nucleus as the 
result of the induced liver apoptosis 4 hours after administering FasL. The extent of liver 
apoptosis after the FasL treatment is subject specific as shown as an example for two 
different mice in B. LD= Liver Disease. 
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Healthy Mice 
Pearson Correlation Coefficient (r2) 
 1 2 3 4 5 Mean +/- STD 
IDIF vs. ABS 0.96 0.92 0.93 0.97 0.97 0.95 +/- 0.024 
Liver Data vs. Fitted Curve 0.99 0.97 0.94 0.92 0.93 0.95 +/- 0.028 
Lung Data vs. Fitted Curve 0.99 0.93 0.99 0.99 0.85 0.95 +/- 0.056 
 
Table 4.1: Validation of image derived input function (IDIF) against the reference 
arterial blood samples (ABS) and comparison of the two-compartment model output 
with the corresponding dynamic FMT data of healthy mice. 
 
 
Mice with Liver Disease 
Pearson Correlation Coefficient (r2) 
 1 2 3 4 5 6 
Mean +/- 
STD 
IDIF vs. ABS 0.94 0.76 0.76 0.95 0.85 0.87 0.86 +/- 0.083 
Liver Data vs. Fitted 
Curve 0.88 0.9 0.98 0.9 0.92 0.97 0.92 +/- 0.042 
Lung Data vs. Fitted 
Curve 0.95 0.93 0.97 0.92 0.83 0.91 0.92 +/- 0.047 
 
Table 4.2: Validation of image derived input function (IDIF) against the reference 
arterial blood samples (ABS) and comparison of the two-compartment model output 
with the corresponding dynamic FMT data mice with experimentally induced liver 
apoptosis. 
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Healthy Mice 
Mean +/- STD 
Mice with Liver Disease 
Mean +/- STD 
 k1 (sec
-1) k2 (sec
-1) k3 (sec
-1) k1 (sec
-1) k2 (sec
-1) k3 (sec
-1) 
Liver 0.0195 +/- 0.022 
0.133 +/- 
0.113 
0.0055 +/- 
 0.0024 
0.0134 +/- 
0.0094 
0.074 +/- 
0.066 
0.0092 +/- 
0.012 
Lung 
6.8x10-4  
+/- 3.7 
x10-4 
0.29 +/- 
0.21 
0.0019 +/-  
0.0011 
0.0161+/- 
0.0094 
0.48 +/- 
0.39 
0.0031 +/- 
0.0036 
 
Table 4. 3: Rate Constants of ICG Pharmacokinetics in the Lung and Liver of Healthy 
Mice and Mice with Liver Disease. The observed increase in ICG rate constants of lung 
is associated with the experimentally induced endothelial cell apoptosis and vascular 
lesions after FasL administration. The slow excretion rate of ICG from the systemic 
circulation in mice with liver disease compared to healthy mice can be associated to the 
sluggish ICG uptake rate of the liver in mice with liver disease. ICG is mainly cleared 
through the liver into the bile without undergoing any modification.  
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4.4 Discussion 
 Dynamic FMT systems can be used to determine the biodistribution of a multitude 
of injectable agents and can be used in conjunction with organ specific dyes to acquire a 
general assessment of organ function. We presented DyFMT as preclinical imaging tool 
for assessing alterations in fluorescent tracer pharmacokinetics pharmacokinetics and 
biodistribution in relation to disease states.   
 In this study, we imaged healthy and diseased mice with high temporal resolution, 
during the disappearance of ICG from systemic circulation, the heart, and its time 
resolved uptake in the liver and lung. ICG is a well-characterized probe, approved for a 
variety of clinical endpoints such as measuring the hepatic blood flow to test liver 
function (El-Desoky et al.; Kimura et al.; Ott; Seifalian et al.). ICG binds to plasma 
proteins, such as albumin, and is mainly removed from the circulation by the liver (Ott; 
Berezin, Guo, Akers, et al.). Dynamic fluorescence mediated tomography (DyFMT) was 
made possible by co-registering data collected using our fiber based, video-rate FMT 
system (Metasebya Solomon et al.) with preclinical microCT data as an anatomical 
reference. To extract ICG concentration over time from our DyFMT data in selected 
regions of interest, we choose three ROIs, one in the heart, lung and in liver based on 
manual segmentation guided by anatomical x-ray CT projections.  
 A measurement of the input function is required for most models characterizing the 
kinetic behavior of substances of interest in tissue in vivo. Measurement of the plasma 
input function enables accurate quantification of dynamic FMT data. Derivation of the 
input function from DyFMT images is the most attractive method because of its non-
invasive nature and because it simplifies the scanning protocol. Therefore, we 
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demonstrated the feasibility of implementing time traces from the heart region as image-
derived forcing function. We demonstrated that there is high temporal correlation 
between IDIF and its corresponding reference arterial blood samples for each mouse. 
Obviously, blood sampling is very invasive and very inconvenient for small animal 
imaging especially due to their small blood vessels and small blood volume. The mean 
Pearson r-values were 0.95 ± 0.024 and 0.86 ± 0.083 in healthy mice and in mice with 
liver disease respectively. 
 We demonstrated the feasibility of distinguishing the uptake rate of two different 
organs, lung and liver. The overall ICG uptake rate of liver was hundredfold higher than 
the lung as expected since ICG is mainly cleared through the liver. Furthermore, we 
demonstrated the feasibility of distinguishing healthy vs. diseased organs based on 
significant difference between the estimated ICG kinetic rate constants of liver and lung 
regions in healthy mice and mice with hepatic disease. For instance, we observed a 
decrease in plasma clearance of ICG in diseased mice, which is associated with the slow 
transport rate through the plasma membrane of hepatocyte. The estimated k1 value, 
which decreased from 0.02 ± 0.022 in healthy mice to 0.013 ± 0.0094 in diseased mice, 
successfully predicted the status of the hepatic function. In addition, we observed an 
increase in the ICG rate constants of the lung and liver. The average overall ICG uptake 
rate of liver and lung, for instance, increased from 7.4x10-4 to 1.48x10-3 sec-1 and 4.46x10-6 
to 1.03x10-3 sec-1, respectively. The fitted ICG concentration curves generated using the 
two-compartment model showed high temporal correlation with the corresponding lung 
and liver ICG time courses data in healthy mice and mice with liver disease (r-values 
were 0.95 ± 0.059 and 0.95 ± 0.028 for lung and liver regions of healthy mice 
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respectively and 0.92 ± 0.047 and 0.92 ± 0.042 for lung and liver respectively in diseased 
mice). The difference between healthy and diseased mice kinetic parameters of the lung 
and liver is associated with the induced morphological changes of cell bodies and the 
nucleus (in liver) and endothelial cells that express Fas receptors (in both lung and liver) 
as previously shown in the literature (Goetz et al.; Janin et al.; Ogasawara et al.).  
 Previous two-dimensional fluorescence reflectance imaging (FRI) has been used to 
monitor the biodistribution of newly developed contrast agents and effects of drugs on 
excretory systems function (Achilefu and Dorshow; Hillman and Moore; Hillman et al.; 
Welsher, Sherlock and Dai; Amoozegar et al.). For instance, dynamic imaging via 
fluorescence reflectance imaging (FRI) recently allowed segmentation of various internal 
organs (Hillman and Moore; Welsher, Sherlock and Dai); In addition, Amoozegar et al. 
has further demonstrated the capacity of dynamic FRI to evaluate healthy and diseased 
organs based on the presence of abnormally altered time courses (Amoozegar et al.). The 
study showed change in ICG uptake rates in the liver and kidney following liver damage 
compared to healthy animals by visual assessment and comparison with ex-vivo studies. 
The strength of the current DyFMT-CT study is that we further extended this approach 
by implementing a two-compartment model to quantify the extent of damage on the 
target organs based on the changes of the kinetic parameters. Furthermore, the current 
DyFMT-CT system has improved deep tissue sensitivity, volumetric localization and 
increased quantitative accuracy compared to the dynamic FRI.  
 The feasibility of fluorescence tomography for in vivo dynamic imaging has been 
previously reported (Alacam and Yazici; Alacam, Yazici, Intes, et al.; Alacam, Yazici, 
Intes, Nioka, et al.; Alacam, Yazici, Serdaroglu, et al.; Cuccia et al.). For instance, Liu et 
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al. quantified the uptake and washout rate of ICG in the liver, where optical imaging was 
acquired at a 1.1 min/frame using their hybrid fluorescence DOT and micro-CT system 
(Liu et al.). The rate constants (uptake rate (k1=0.0036 sec
-1) and washout rate of 
(k3=0.00069 sec
-1)) were ten times slower than we predicted, which could be associated 
to the slow acquisition rate incapability to capture the fast dynamics of liver. Moreover, 
their image acquisition time, 1.1min/frame is unsuitable for capturing fast dynamics of 
the first few minutes in regions such as the heart, although it may be adequate for the 
slow dynamics of the liver. In addition, image acquisition times in the range of minutes is 
unsuitable for capturing the early fast-changing signals associated with various optical 
contrast agents. To a significant extent, the system presented in this paper addresses 
many of these difficulties. 
 The difficulty in FMT image segmentation is compound by the low spatial 
resolution in optical imaging, which rapidly degrades with imaging depth due to the high 
scattering of light in tissues (Hillman et al.). Therefore, optical imaging can leverage 
anatomical information to improve accuracy during processing and image 
reconstruction. For instance, we implemented manual segmentation to extract relative 
ICG concentration from three target regions. An important future area of work is in 
incorporating automatic or semi-automatic statistical clustering algorithms. The 
possibility of implementing segmentation algorithm to delineate the different organs 
based on differences in the kinetics of injected contrast agents also remains a question 
for future investigation. Another limitation of low spatial resolution is spillover and 
partial volume effects that would affect the accuracy of ROI based input functions.  The 
spillover and partial volume effects on the selected ROIs have not been corrected for in 
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this study. Therefore, another area of future work is to adapt spillover and partial volume 
correction algorithms developed for dynamic PET and MRI imaging systems for 
DyFMT platform (Fang and Muzic; Laforest et al.; van der Weerdt et al.; Wu, Hoh, et al.; 
Wu, Huang, et al.). With these improvements, the accuracy of IDIF would remain 
consistent across multiple optical contrast agents despite the variance introduced by their 
different perfusion rates.  
 The current FMT system setup has high dynamic range and linear response and 
accurate localization at various depths as shown in previous studies (Metasebya Solomon 
et al.). However, several potential improvements of the fiber-based, video-rate FMT 
system can still be identified. Possible extensions on the current design include extending 
the FMT field of view for whole-body imaging. The DOT imaging array shape and size 
can be designed based on the individual application. For example, the imaging array 
could have a cylindrical shape with extended sources and detectors for whole-body 
coverage. The potential for an expanded fiber array system with up to 48 sources and 48 
detectors has been demonstrated for brain imaging in humans (White et al.). A higher-
density imaging array could also potentially increase the resolution, particularly at the 
shallower depths for accurate estimation of the IDIF (Culver, Ntziachristos, et al.). 
4.5 Conclusion 
 In this study, we presented video-rate, fiber-based FMT, a non-invasive in vivo 
imaging tool for quantitative pharmacokinetics and biodistribution studies. We imaged, 
with high temporal resolution, the disappearance rate of ICG from systemic circulation 
and its time-resolved uptake and clearance in the liver and lung in healthy mice and mice 
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with experimentally induced acute hepatic apoptosis. In addition, we validated the 
feasibility of implementing time traces extracted from highly vascularized region-of-
interest as a forcing function rather than acquiring arterial blood samples invasively. The 
time courses of the heart region are used as an image-derived input function for a two-
compartment model to compute the uptake and clearance rate of ICG from the lung and 
liver regions. Comparisons between the ICG kinetics parameters before and after drug 
treatment demonstrate the capacity to assess organ function and drug-related acute 
toxicity. Although we have used a linear compartment model in these studies, more 
complex models could be used successfully. In summary, tracer kinetic modeling 
combined with fluorescence dynamic tomography provides a powerful pharmacokinetic 
analysis tool using newly developed diagnostic optical agents with a potential for 
detecting the disease state affecting internal organs and monitoring their response to 
therapeutic agents.  
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Chapter 5 
 
Detection of Enzyme Activity in 
Orthotopic Murine Breast Cancer by 
Fluorescence Lifetime Imaging Using 
Fluorescence Resonance Energy 
Transfer-based Molecular Probe 
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5.1 Introduction 
 Molecular signatures of cancer tissues include up-regulated signaling receptors and 
enzyme expression. For example, up-regulation of integrin receptors in tumors is 
associated with metastatic spread (Sloan et al.). Likewise, increased activity of members 
of the matrix metalloproteinase (MMPs) family by in cancer tissue can also be an 
indication of metastatic potential (Roy, Yang and Moses). Enzyme activity can be 
diagnostic and prognostic in cancer and other diseases. For instance, MMPs are 
biomarkers for diagnosis and prognosis in cancer as they have been implicated as 
mediators of tumor growth, invasion and metastasis (Bremer, Tung and Weissleder; 
Himelstein et al.; Fingleton; Weissleder et al.). MMP inhibitors are under investigation as 
anti-cancer agents (Roy, Yang and Moses). 
Preclinical optical imaging with fluorescent contrast agents has become prominent in 
recent years due to the high sensitivity and high throughput nature of this versatile 
modality. Fluorescent molecular probes can be administered for rapid detection of 
disease throughout the body of small animals, economically and without ionizing 
radiation. Fluorescence techniques can be further enhanced by sensing mechanisms such 
as spectral shifts, quenching and fluorescence lifetime changes that may occur due to 
molecular interactions and environmental conditions. Optical imaging with fluorescent 
molecular probes is an economical, high throughput modality for non-invasive detection 
these cancer signatures in animal models of cancer. 
 Fluorescent molecular probes include “always on” agents that rely on target binding 
in tissues or “activatable” agents that report molecular interactions by signal 
enhancement mechanisms. For “always on” agents, measured fluorescence intensity is 
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used as a measure of concentration in tissue, similar to nuclear imaging. An example 
would be a ligand for an up-regulated receptor that bears a near-infrared (NIR) dye such 
as IS750.  This contrast agent has a high affinity for the αvβ3 integrin receptor (ABIR) 
and has been used in experimental animal models for imaging tumors. Activatable 
probes used in fluorescence-based imaging are optically invisible or at least display 
reduced fluorescence until molecular activation at the disease site.  These include enzyme 
substrates with fluorescent dyes in close proximity which often employ fluorescence 
resonance energy transfer (FRET) in addition to other quenching mechanisms (Berezin 
and Achilefu).  The enhancement of fluorescence intensity at the site of disease may be 
great enough in intensity for visualization, but may not totally reflect molecular events 
within the disease site. Measurement of fluorescence lifetime alteration can be 
additionally utilized to verify that the observed fluorescence is indeed mediated by a 
molecular target and not from other processes(Chang et al.). 
 Fluorescence lifetime is an intrinsic property of fluorescent reporters that is not 
dependent on concentration but can reflect changes in the environment. Often, the 
quantum yield is directly related to the fluorescence lifetime: quenching of the 
fluorescent reporters in an enzyme activatable probe results in lower quantum yield and 
shortening of the molecular probe’s fluorescence lifetime. In the intact FRET pair, the 
quantum yield and the lifetime of the donor are lower due to the transfer of the 
excitation energy of the donor to the acceptor (Berezin and Achilefu). Both the quantum 
yield and the lifetime are subsequently restored to the free dye values after proteolysis 
leading to an increase in fluorescence intensity and lifetime values of the donor.  
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 Figure 5.1 shows a schematic of the mechanism of action of enzyme activatable 
probe such as the one used in this study. The donor (D) is a NIR fluorescent reporter 
attached via a cleavable peptide linker to an acceptor (A) molecule. The absorption 
properties of the acceptor overlap with the emission properties of the donor attenuating 
fluorescence and shortening lifetime of the donor. Upon enzyme-mediated hydrolysis, 
the emission properties of the donor are restored. Previously reported protease 
activatable molecular FRET probes have shown to improve the tumor detection 
sensitivity using the intensity signal (Mahmood and Weissleder; Scherer, McIntyre and 
Matrisian). In this report, we demonstrate that fluorescence lifetime measurement 
confirms that the observed fluorescence in the syngeneic tumor is, in part, a result of 
MMP-mediated hydrolysis and subsequent liberation of the proteolytic fragments from 
close proximity that caused the initial quenching. 
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Figure 5.1: Cartoon of FRET-based fluorescent molecular probe and restoration of 
fluorescence after enzyme mediated hydrolysis of the connecting peptide by protease 
enzymes. The fluorescence quantum yield and fluorescence lifetime of the donor are 
increased as the donor and acceptor are separated. In the case of MMP750, the donor 
and acceptor are identical fluorophores. 
 
 Herein, we examined an MMP-sensitive activatable fluorescent construct and an 
“always-on” ABIR-targeted fluorescent probe in a murine orthotopic breast cancer 
model using both fluorescence intensity and fluorescence lifetime imaging. While both 
agents produced good tumor contrast in this model, only the activatable probe showed a 
significant increase in fluorescence lifetime validating the upregulated enzyme activity 
due to presence of the tumor. This study demonstrates the potential of fluorescence 
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lifetime imaging for improving the knowledge of whether the molecular events that are 
observed are actually target related with FRET-based activatable probes. 
5.2 Methods 
5.2.1 in vitro Spectroscopy In vitro Spectroscopy 
 IntegriSense 750 (IS750) and MMPSense 750 FAST (MMP750) were purchased 
from VisEn Medical (Bedford, MA) and prepared according to manufacturer’s 
instructions. IntegriSense750, MMP750 and MMP-activated MMP750 were diluted in 
4% (w/v%) bovine serum albumin (BSA) in phosphate buffered saline (PBS) for 
spectroscopy. A 20 µL MMP750 solution was then added and incubated at 37 ºC for 3 
hr. Activation of MMP750 was confirmed by an increase in fluorescence intensity in 
cuvettes (ex/em: 740/755-900 nm) of the activated solution relative to the control 
solution under identical conditions. Fluorescence lifetime (FLT) measurements were 
performed with using 780 nm NanoLed® (impulse repetition rate 1 MHz) excitation at 
90º to the a time-correlated single-photon-counting detector at 820 nm, 26 nm bandpass 
(Horiba). The fluorescence lifetime was recorded on a 50 ns scale until a peak of 5,000 
counts. The instrument response function was obtained using a Rayleigh scatter of 
Ludox-40 (0.05% in water) in an acrylic transparent cuvette at 780 nm emission. Decay 
analysis software (DAS6 v6.1; Horiba) was used for lifetime calculations. The goodness 
of fit was judged by χ2 values, Durbin–Watson parameters, as well as visual observations 
of fitted line, residuals, and autocorrelation functions. 
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5.2.2 In vivo Imaging 
 All animal studies were performed according to protocols approved by at 
Washington University School of Medicine Animal Studies Committee for humane care 
and use of laboratory animals. Luciferase-transfected 4T1 mouse mammary carcinoma 
cells (4T1luc, Sibtech, Brookfield, CT) cultured in DMEM media were injected 
subcutaneously into left and right mammary fat pads. 
 Mice were anesthetized with ketamine (85 mg/kg) and xylazine (15 mg/kg), IP for 
depilation, intravenous injections and initial post-injection imaging. For extended and 
subsequent imaging, isoflurane gas (2% v/v in 100% O2) was delivered via nosecone for 
maintenance of anesthesia. Imaging agents were administered according to 
manufacturer’s recommendations, 1 nmol per mouse, via lateral tail vein of 6-8 week-old 
female balb/c nude mice (n=3) provided by NCI (NIH).  
 Time-domain diffuse optical imaging of living mice was performed using the 
eXplore Optix MX2 system (Advanced Research Technologies, Montreal, Canada) as 
reported previously (S. Achilefu, S. Bloch, et al.). Briefly, the animals were positioned 
supine on the heated imaging platform. Pre-injection scans were performed to assess 
background and autofluorescence signals. Scans were again performed immediately post-
injection and at 4-6 hr and 24 hr post-injection. Regions of interest including tumor and 
non-tumor tissue were raster-scanned at 780 nm excitation with emission detection 
centered at 830 nm in 1.5 mm steps. Fluorescence intensity and lifetime values were 
determined by integration or single exponential fitting of the acquired temporal point 
spread function (TPSF) fluorescence decay curves for each measurement using Optiview 
software (Advanced Research Technologies). Images were created by mapping each 
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value to the corresponding location on a white light reference image of the mouse. Mean 
fluorescence intensity and lifetime values for tumor and non-tumor tissue regions of 
interest (ROI) for each mouse were selected and reported for analysis. 
 For reference and ex vivo fluorescence biodistribution assays, images were also 
captured using the Pearl NIR fluorescence imaging system (LiCor Biosciences, Lincoln, 
NE). The biodistribution of probes was assessed using the simple method described 
previously (S. Achilefu, R. B. Dorshow, et al.; Bugaj et al.).  At 24 h post-injection, 
aliquots of blood and pieces of major organs (tumor, heart, kidney, lung, spleen, 
stomach, intestine, muscle, liver, skin and brain) were harvested and placed on a clear 
plastic petri dish for imaging. Fluorescence images were acquired as described above. 
Mean fluorescence intensity was determined for each tissue by ROI analysis and 
combined for each group for statistical analysis.  
5.2.3 Statistical Analysis 
 Mean fluorescence intensity and FLT values of ROIs for each group were compared 
using student’s t-test with α = 0.05 set for significance. Fluorescence biodistribution 
ROI data were averaged for each organ tissue for IS750 and MMP750 and plotted 
together for comparison. 
5.3 Results 
 The in vitro activation of MMP750 by the enzyme led to the significant (~2X) 
increase in fluorescence as shown in Figure 5.2A. Such increase in fluorescence was 
apparently due to the enzymatic cleavage of the peptide linker leading to the separation 
of the donor from the acceptor. As expected, a simultaneous increase of the decay slope 
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(Figure 5.2B) demonstrated an increase in the fluorescence lifetime from 0.58 ns to 0.73 
ns, unequivocally demonstrating a reduction in FRET. 
 
 
 
Figure 5.2: (A) Fluorescence steady state spectra of MMP750 before and after 
enzymatic activation by MMP-2 for 3 hr. The increase in fluorescence intensity 
confirmed partial activation by enzyme-mediated hydrolysis. (B) Fluorescence decays of 
MMP750 before and after MMP treatment demonstrating a shift in FLT from 0.58 ns to 
0.73 ns due to decreased FRET efficiency after activation. 
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 Having demonstrated the fluorescence lifetime increase in MMP750 upon 
interaction with MMP and stable fluorescence lifetime of IS750, we administered the 
probes into small animal tumor models for in vivo imaging. Both IS750 and MMP750 
showed tumor-specific uptake in vivo by fluorescence intensity imaging (Figure 5.3A). 
 
 
Figure 5.3: (A) Planar fluorescence imaging of mouse with orthotopic breast tumors at 
6 and 24 hr after injection of MMP750. (B) Fluorescence biodistribution image (inset) 
and ROI data for organ tissues 24 hr after injection of either MMP750 or IS750. Arrows 
indicate 4T1luc tumors. 
 
 Fluorescence intensity values were highest for the ABIR-targeted probe immediately 
after injection in the tumor and non-tumor regions and decreased with time. In contrast, 
MMP750 was relatively silent after injection and fluorescence signal increased with time, 
particularly in the tumor regions. Ex vivo tumor fluorescence at 24 h post-injection was 
higher in the tumor than other tissues (Figure. 5.3B), with 20-fold higher than muscle for 
both probes (n=3). Autofluorescence and signal from the GI tract was less than 10% of 
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the signal after molecular probe administration and did not affect the measurement of 
fluorescence intensities or lifetimes. 
 Example fluorescence decay curves and nonlinear regression fits are given in Figure. 
5.4. Laser power and integration time were automatically adjusted during scanning to 
ensure adequate photon counts for fitting. The tails of the TPSF curves were fit from 2-
6 ns (Figure. 5.4, black lines) for image map construction.  
 
 
Figure 5.4: Representative normalized fluorescence decay curves (TPSF) in vivo FLT 
imaging tumor ROIs with single exponential least squares nonlinear regression (black 
line) from 2 ns to 6 ns (shaded) for MMP750 post-injection (MMP750t0) and 4 h post-
injection (MMP750t0) and for IS750 post-injection (IS750t0).  
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Figure 5.5: Fluorescence intensity and lifetime maps of mice with orthotopic 4T1luc 
breast tumors immediately after (A and C) and 4-6 hr after (B and D) injection of 
MMP750. The fluorescence intensity maps show low fluorescence immediately after 
injection (A) and high signal from the tumors at 4-6 hr after injection (B, arrows). The 
fluorescence lifetime map is relatively flat with average FLT of 0.63 ns immediately after 
injection (C). At 4-6 hr after injection, the tumor areas show a higher FLT (0.76 ns) 
relative to non-tumor regions. Corresponding image maps show different behavior for 
the “always on” probe. The fluorescence intensity maps show higher signal immediately 
after injection (E) and from the tumors at 4-6 hr after injection (F, arrows). The 
fluorescence lifetime map is relatively flat immediately after injection (G). At 4-6 hr after 
injection, the tumor areas show a shorter FLT relative to non-tumor regions (H). 
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 Intensity maps created by integration of the fluorescence decay curves produced 
image maps showing good tumor contrast. The fluorescence intensity of MMP750 was 
very low immediately after injection and increased about 10-fold by 6 hr post-injection 
(Figure 5.5A and 5.5B, respectively). On the other hand, IS750 fluorescence was high 
immediately after injection (Figure 5.5E). Fluorescence signal from the tumor regions 
was significantly higher (P<0.01) for animals in both groups by 6 hour post-injection 
(Figure 5.5B and 5.5F).  
 In vivo FLT imaging showed that the measured tumors FLTs for MMP750 were 
elevated at 4-6 hour post-injection (Figure 5.5D) relative to earlier time points (Figure 
5.5C). The FLT maps showed a more diffuse pattern than the intensity maps with 
increase in FLT in the tumor and peritumoral regions. For IS750, the FLT maps were 
relatively flat at corresponding time points (Figures 5.5G and 5.5H). FLT values from in 
vivo ROI analysis are shown in Figure 5.6. 
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Figure 5.6: Graphical comparison of in vivo FLT values for tumor ROIs immediately 
after (post-inj) and at 4-6 hour after intravenous administration of NIR fluorescent 
molecular probes. The measured FLT values for MMPSense750 FAST at 4-6 hr were 
significantly higher (*P<0.01) than post-injection. FLT values were not significantly 
different for these time points with IntegriSense750. 
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 For MMP750, the fluorescence lifetime was 0.63+/-0.02 ns immediately post-
injection and increased with time. At 4-6 hr post-injection, the FLT had increased 
significantly (P<0.01) to (0.76+/-0.02 ns) in the tumor region. For IS750, the average 
FLT values did not change significantly (1.11+/-0.01 ns immediately post-injection and 
1.10+/-0.03 ns at 4-6 h post-injection). In the tumor regions, FLT values were slightly 
lower (1.09+/- 0.03 ns) than non-tumor regions (1.11+/-0.03 ns). Expression of MMP-2 
and MMP-9 in the 4T1luc tumor tissues was confirmed by immunohistochemistry 
(Figure 5.7).  
 
Figure 5.7: H&E stained section of orthotopic 4T1luc tumor tissue (A) and 
immunohistochemistry for MMP-2 (B) and MMP-9 (C). Brown color indicates areas 
with high MMP expression in these tumors. 
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5.4 Discussion 
 Enzyme activatable fluorescent probes promise higher disease-specific contrast 
relative to “always on” targeted molecular probes by fluorescence enhancement only 
within the tissue of interest. The contrast enhancement mechanism of fluorescence 
activation is unique to optical imaging. Detection of cancer-related enzyme activity using 
protease-activatable fluorescent probes has high potential for use in staging of primary 
cancers and detection of metastases.  
 In the current study, excellent tumor-specific contrast was achieved within 4-6 hr 
after injection with both the activatable MMP-sensitive and “always on” integrin-targeted 
NIR fluorescent molecular probes in the orthotopic breast cancer model. The orthotopic 
breast tumors developed from implanted 4T1 cells syngeneic to the balb/c mouse line  
are known to produce metastases to the lung and lymph nodes (Tao et al.). This 
aggressive tumor model is representative of fast-growing and invasive human breast 
cancer. MMP activity and ABIR expression are biomarkers of breast cancer considered 
to indicate the aggressiveness of the disease (Daniele et al.; McGowan and Duffy).. 
 The molecular targets, MMPs and ABIR, are ubiquitously expressed in both target 
and non-target tissues, although at unequal levels (Roy, Yang and Moses; Sloan et al.). 
Thus it is not surprising that some fluorescence signal is observed in non-target tissues. 
Enhancement of signal from the MMP probe was observed in these tissues and results in 
some fluorescent background rendering the tumor-to-normal contrast produced by this 
agent almost equal to that of the “always on” fluorescent probe. It is therefore 
imperative that the activation of this probe be established to distinguish enzyme activity 
from other modes of contrast including nonspecific accumulation. The activation of 
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MMP750 was confirmed in this study by the change in FLT that resulted from reduction 
in FRET as the peptide sequence was cleaved as depicted in Figure. 5.1. FLT imaging 
provides confirmatory evidence of activation by detecting changes in FRET. 
 Unsurprisingly, the FLT increase due to activation of MMP750 is seen in the tumor 
tissue and the surrounding mammary tissue as well (Figure. 5.5D). High MMP activity in 
the tumor periphery is expected as MMPs are expressed within the tumor stroma and on 
the invasive front (Roy, Yang and Moses). Thus the FLT map demonstrates the real 
MMP activity in tissue rather than just accumulation.  This study shows that detection of 
molecular probe activation using FLT-based imaging has significant advantages over 
other strategies such as inclusion of a spectrally distinct, reference fluorescent reporter 
either co-injected (Baeten et al.) or as part of the probe construct (Scherer, McIntyre and 
Matrisian). The use of a single fluorophore as both donor and acceptor facilitates 
synthesis of activatable probes, providing that adequate quenching is established.  
 A shortcoming of enzyme-activatable probes, that is not often discussed, is whether 
there is significant tumoral accumulation of fluorescent proteolytic fragments that were 
activated distal to the tumor site. Accumulation of the proteolytic fragments might 
exaggerate the apparent enzyme activity within the tumor tissue. Further studies are 
needed to assess this type of nonspecific activation and the fates of the probe fragments 
within the body. Fluorescent probes with improved enzyme selectivity will improve 
detection and differentiation of cancer-related enzyme activity from other causes such as 
inflammation (Bremer, Tung and Weissleder). MMP750 resulted in exceptional tumor-
specific contrast by fluorescence intensity that was apparently enzyme mediated. Good 
tumor-normal contrast was obtained within 4-6 hr after injection, a significant 
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improvement over larger, polymeric activatable probes which require 8-24 hr (Baeten et 
al.).  
5.5 Conclusion 
 For quantitative measurement of enzyme activity, nonspecific activation must be 
minimized or other methods developed to separate the level of activation from that of 
concentration. Here we have presented FLT imaging as one possibility. FLT imaging has 
the potential for directly assessing changes in FRET due to enzyme activity and is 
relatively simple and inexpensive relative to other methods such as reference probe co-
administration and multimodal imaging. Measurement of the change in FRET upon 
activation was performed using a single excitation/emission and simple data analysis. 
FLT imaging using NIR fluorescent FRET probes is a promising technique that has 
translational potential in regions accessible to optical imaging such as skin, GI and breast 
cancers. This technique may also be useful for fluorescence guidance of surgery. 
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